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Targeted Inhibition of Sp1 Transcription Factor and Antiangiogenesis of Human Pancreatic Cancer
Publication No.________
Zhiliang Jia, Ph.D.
Supervisory Professor: Keping Xie, M.D., Ph.D.

Transcription factor Specificity Protein 1(Sp1) is reported to be essential for
vascular endothelial growth factor (VEGF) constitutive expression in human
pancreatic adenocarcinoma. The definitive role of Sp1 in angiogenesis, the
impact of anti-angiogenic therapy on the Sp1/ VEGF signaling and the Sp1
signaling alteration on the anti-angiogenic therapy effect are unclear. The
understanding of Sp1 regulation on VEGF and their interactions has significant
clinical implications.

Sp1 and VEGF expression and microvessel density (MVD) were analyzed using
pancreatic cancer patients specimens through immunohistochemistry staining.
The impact of Sp1 expression alternation on angiogenesis and tumor
progression in nude mice were determined by knockdown Sp1 with smallinterfering RNA (siRNA). Sp1 protein expression was correlated with the MVD (P
< 0.001) and VEGF expression (P < 0.05). In mouse models, tumor progression
and metastasis were inhibited after knockdown of Sp1 expression. The antitumor

vii

activity was correlated with the down-regulation of Sp1 downstream angiogenic
factors caused by Sp1 knockdown.

Sp1 and its downstream angiogenic genes expression were suppressed by
mithramycin treatment both in vitro and in vivo. Moreover, mithramycin treatment
reduced MVD in vivo. This was consistent with the down-regulation of VEGF,
PDGF, and EGFR. Human xenograft pancreatic tumor growth was suppressed
by Bevacizumab treatment. Both western blot and immunohistochemistry
staining revealed that Sp1 and its downstream angiogenic genes expression
were up-regulated by Bevacizumab treatment. Bevacizumab and mithramycin
combination treatment synergistically suppressed tumor growth in vivo. This is
correlated with the down-regulation of Sp1 and its downstream angiogenic genes
expression. Bevacizumab treatment may trigger a positive feedback to upregulate angiogenic factors through Sp1 trans-activation and this mechanism can
be diminished by mithramycin treatment.

Combination treatment of mithramycin and tolfenamic acid which has been
shown to facilitate Sp1 protein degradation had synergistic cell growth inhibition
effect in vitro. In vivo, metronomic low-dose combined treatment of mithramycin
and tolfenamic acid produced tumor suppression in mouse model. Gene
expression analysis showed that the combination treatment synergistic downregulated Sp1 and its downstream angiogenic molecule VEGF.

viii

In summary, experimental results and clinical research suggested that Sp1
signaling is very important for angiogenesis of pancreatic cancer. Mithramycin
treatment down-regulated Sp1 protein through interpose its transcription and
decreased Sp1 downstream angiogenic genes. These down-regulations were
correlated with the antitumor activity. Synergistic down-regulation of Sp1 and
decreased expression of its downstream angiogenic molecules in turn significant
reduced the angiogenic potential of pancreatic cancer cells and is an effective
anti-angiogenesis strategy. Therefore, this study showed that Sp1 is a key factor
of angiogenesis and manipulation of Sp1/VEGF signaling has clinical implication
in anti-angiogenic therapy of pancreatic cancer.
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BACKGROUND
PANCREATIC CANCER IS A LETHAL DISEASE
The pancreas is an organ of the digestive system. It has two major functions that
are performed by its two components respectively. The exocrine pancreas, which
consists of ductal and acinar elements and is about 80 percent of the organ,
produces several enzymes that are secreted and can digest food in intestine; and
the endocrine pancreas, which mainly consists of islets and is about 20 percent
of the organ, makes hormones that can enter circulating system and have
different functions [1]. Pancreas tumors may occur in exocrine part of pancreas
(which are the classic pancreatic adenocarcinoma) or in endocrine part of
pancreas.
Pancreatic cancer is the eighth cause of death and the thirteenth incidence
cancer worldwide [2, 3]. In United State, it is currently the fourth leading cause of
cancer related deaths [3]. According to the American Cancer Society, there were
about 42,470 new pancreatic cancer cases and about 35,240 people die from the
disease in 2009. Age is the most important predictor of pancreatic cancer. It is
rare before 45 and the incidence rises greatly after that [4]. The male to female
ratio is 1.3:1. The number one risk factor of pancreatic cancer is smoking and
diet is the second risk factor associated with this disease. Consumption of animal
protein and fat is associated with increased risk and vegetable diet is associated
with decreased risk [2, 4, 5]. Several medical conditions including diabetes,
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pancreatitis, gastrectomy and cholecystectomy are also associated with
increased risk of pancreatic cancer [6-12].
Because of the non-specificity and late appearance of symptom, pancreatic
cancer is difficult in diagnosis. It is an aggressive type of tumor and the systemic
treatments availability is limited. The five-year survival rate of pancreatic cancer
patients is only about 5 percent and median survival duration is about 4 to 6
months (from diagnosis to death). Most people were diagnosed at advanced
stages [3, 13, 14]. It is highly resistant to chemotherapy and radiotherapy. The
pancreatic cancer cells are highly metastasis in vivo, mostly to liver and lung.
Lots of angiogenesis and invasion key regulatory molecules are reported to be
aberrantly expressed [15, 16].
Most of the pancreatic tumors are primary pancreas tumors including exocrine
tumor, endocrine tumor and non-epithelial tumors. Pancreatic tumor that
metastasizes from other organ is about 3 to 11 percent [17-19]. In pancreatic
carcinoma, ductal adenocarcinoma is about 80 to 85 percent and 90 percent if
the variants are included [20, 21]. The variants of ductal carcinoma may include
adenosquamous carcinoma, which has squamous component; mucinous
noncystic carcinoma, which has well differentiated glands that consists of more
than 50 percent of mucinous tissue; signet-ring cell carcinoma, which consists of
a dyshesive population of malignant cells infiltrating the pancreas and has
cytoplasmic mucin vacuoles that compress the nucleus and is similar to signetring cell carcinoma of stomach; and several other rare variants [22-24]. Besides
2

ductal adenocarcinoma, there are some other types of pancreatic tumors that
belong to pancreatic exocrine tumor, such as acinar cell carcinoma,
pancreatoblastoma,
cystadenocarcinoma,

solid-pseudopapillary
intraductal

carcinoma,

papillary-mucinous

tumor,

serious
mucinous

cystadenoma, osteoclast-like giant cell tumor, miscellanceous carcinoma and so
on. Pancreatic endocrine tumors are only 0.5 to 4 percent of all pancreatic
primary tumors. Most of the pancreatic endocrine tumor occurs in adult people. It
mainly includes insulinoma, small cell carcinoma, glucagonoma, gastrinoma and
so on. Non-epithelial tumors have 2 types, soft tissue tumor and lymphoma. This
dissertation focuses on pancreatic ductal adenocarcinoma angiogenesis and
experimental therapeutics. The word pancreatic cancer in this dissertation was
assumed to be pancreatic ductal adenocarcinoma without specific explanation
after this point.
Generally pancreatic cancer appears at pancreas head. It may infiltrate to
adjacent tissue and metastasize to distance organ such as liver and lung. Based
on its histological and cytological characteristics, it seems that pancreatic cancer
is developed from pancreas ductal cell. But research showed each type of cells
of pancreas has the capacity to dedifferentiate the duct like phenotype [25, 26].
Genetic engineered mouse models were developed and expected to give a clear
cut answer to the cell origin of pancreatic cancer and beyond [26-29]. Besides
this question, researches also focus on the pancreatic ductal adenocarcinoma
precursors. Pancreatic intraepithelial neoplasm (PanIN), mucinous cystic
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neoplasm (MCN) and intraductal papillary mucinous neoplasm (IPMN) were
identified as pancreatic cancer precursor lesions [30-32]. PanIN that could be
found in the pancreas smaller caliber ducts is the most extensively studied one.
A new nomenclature for classification of duct lesion in pancreas was documented
in 1999 and published 2001 [33]. In addition to the histological and morphological
characters, molecular genetics changes of PanIN development were also
documented [33, 34]. K-Ras mutation was found to be the key molecular event
during the process [26, 35]. Among the complicated signaling network evolved in
PanIN, a small class of molecules, such as p53 and nuclear factor κB (NF-κB),
control the neck, which is the messenger RNA transcription, of the whole network.
Genetic and epigenetic changed molecules and tumor environmental factors,
such as hypoxia, acidosis and so on, directly or un-directly use one or more
transcription factors to modulate tumor cell physiological activities.

TRANSCRIPTION FACTOR AND CANCER BIOLOGY
Transcription factors are protein complexes that are responsible for regulating
gene expression in response to upstream signal [36, 37]. The regulation links cisacting DNA sequence and the corresponding gene expression and may be
activation or repression. Transcriptional activation facilitates RNA polymerase
binding to cis-acting DNA sequence. Transcriptional repression includes the
global or local level interference with the transcription genes directly or indirectly.
The following discussion focuses on transcriptional activation and transcription
factor is supposed to be transcription activator without specific explanation.
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In the genome of life, each gene has a DNA sequence called promoter. It can
control transcription of the gene. Promoter is usually located right before the
coding region and its length may vary in different genes. RNA polymerase needs
to bind to promoter before the beginning of gene transcription [38, 39]. Protein
sequence information in the gene can be transcribed into messenger RNA by
RNA polymerase [40]. RNA polymerase II is mainly responsible for messenger
RNA transcription. Protein synthesis of the gene is then directed by the
messenger RNA that is carrying the information [41]. Transcription factors can
regulate gene transcription by controlling RNA polymerase's access to the
promoter region. To fulfill this function, transcription factors have both ciselement recognition and transcriptional activation. Generally these two functions
are fulfilled by different regions of the protein primary structure.
To fulfill the functions, transcription factors must recruit themselves on promoter
through interaction with specific DNA sequences. Generally each kind of
transcription factor owns one and only one handful structural motifs. The motif
that can bind to promoter is called DNA binding domain. (A protein motif is the
small spatial part of the whole molecule.) Transcription factor may interact with
basal factors or other proteins called co-factor by other portions. The DNAbinding domain of a transcription factor recognizes cis-element [38]. In eukaryotic
life form, most genes’ promoter has the “TATAA” sequence, called the "TATA
box". It is usually located in twenty-five to thirty nucleotides before the
transcription start site. Transcription factors that bind this sequence are called
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TATA-binding protein (TBP). TBP is one of the most important transcription
factors and the main component of general transcription factor TFIID [38, 42, 43].
Chemically,

transcription

factors

bind

cis-element

using

a

combination

of electrostatic and Van der Waals forces. Transcription factors’ bindings to
promoter are sequence specific, because the combination of the chemical
interactions of different transcription factor is specific. DNA binding domain has
several families according to its structure character, such as helix-turn-helix, zinc
finger, winged helix and so on [44-47].
The structure motif(s) of transcription factor fulfill transcriptional activation is
called transcriptional activation domain (TAD). By analyzing the amino acid
sequence, TAD has been classified based on the abundance of particular amino
acid [48, 49]. In this way transcription factor are divided into glutamine rich,
proline rich, acidic and so on. Recently, with the assistant of computational
biology, a nine-amino-acid transcriptional activation domain (9aaTAD) defines a
novel domain classification of the eukaryotic and yeast transcription factor family
[50]. Most researches showed that the transcriptional activation process
accompanied by the conformational changes of both TAD and its binding sites,
although the initiator of the changes may not be the same side all the time [5154].
Transcription factors are important in cell cycle control, development and
intercellular signaling transduction. Some human diseases have been the results
of transcription factors’ mutations. Many transcription factors were found to be
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important for tumor related signaling and were considered to be tumor
suppressors or oncogenes. For example, over 50 percent of tumors contain
a point-mutation or deletion mutation of the p53 gene in human species [55-57].
Several transcription factors, such as hypoxia inducible factor (HIF), Sp1 and so
on, are considered to be important for tumor angiogenesis process [58-63].
Some of them were found to be angiogenic factor of different types of tumors
including pancreatic cancer.

ANGIOGENESIS AND PANCREATIC CANCER PATHOGENESIS
Capillaries are the lifeline of all live tissue including and especially for tumor.
Oxygen and nutritious delivery and waste removal are the basic physiological
function of blood circle system fulfilled ultimately by capillaries. Additionally,
tumor needs to be near capillaries to metastasize to distance, which leads to its
fatality property. Due to the high proliferation rate of tumor cells, tumor keeps on
expansion and invading the around normal tissue. This process totally relies on
the growth of new blood vessels. The physiological process of the new blood
vessels growth from the existing vessel is called angiogenesis [64-66]. There are
two types of angiogenesis. One is sprouting angiogenesis and the other is
intussusceptive angiogenesis. Sprouting angiogenesis enables entire new
vessels to grow from existing blood vessel and occurs at a rate of several
millimeters per day. While intussusceptive angiogenesis actually form new blood
vessel through splitting the existing blood vessel and is also called splitting
angiogenesis [67]. But it is important because it allows a vast increase in the
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number of capillaries with relative limited number of endothelial cells. When there
are not enough resources especially during the embryonic development, it is a
very important way to develop new vessels.
The concept of angiogenesis appears in early 1970’s. It was recognized during
the research of neoplastic as well as non-neoplastic diseases such as psoriasis,
atherosclerosis, rheumatoid arthritis, infantile harmangioms and so on [68-73].
Angiogenesis occurs in not only the pathological process but also the normal
physiological processes including reproduction, development and wound healing.
The following discussion will focus on tumor related pathological process.
Pathological angiogenesis may lead to bleeding, vascular leakage and tissue
destruction.
Angiogenesis is a process orchestrated by a lot of angiogenic factors as well as
angiogenic inhibitors. With the progress of angiogenesis research, lots of natural
angiogenic inhibitors were found and the concept of anti-angiogenic therapy also
sprouted and grew rapidly especially at the mid 1990’s [74-81]. Considering the
fact that angiogenesis is important to tumor growth and metastasis, antiangiogenic therapy may be one potential selection of pancreatic cancer patients.
It may produce enhanced efficacy and long-term survival [66, 82, 83]. The
acquisition of angiogenic phenotype of tumor tissue and its following
maintenance are mainly through over-expression of angiogenic molecules. The
over-expression of the molecules is activated by growth factors, stress factors
and cytokines secreted by tumor cells. Transcription factors between the
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upstream signal factors and downstream angiogenic factors are the neck part of
the regulatory pathway of tumor angiogenesis and maybe a good target [58].
To achieve effective treatment modalities of pancreatic cancer, new targets need
to be identified. It is crucial to fully understand the cellular and molecular
mechanisms of the development and progression of tumor angiogenesis. Lots of
the reported angiogenic and anti-angiogenic factors released by tumor and host
cells are the potential targets [58, 84, 85]. Angiogenesis process is regulated by
the interaction of these factors and then regulates the survival and metastasis of
pancreatic tumor [58, 86, 87]. Among the numerous angiogenic factors
discovered till now, studies have identified vascular endothelial growth factor as a
key mediator of tumor angiogenesis in most tumor types [88-90]. Other identified
angiogenic factors include platelet-derived growth factor (PDGF) and PDGF
receptor [91, 92], fibroblast growth factors (FGF) and their receptors [93, 94],
epidermal growth factor (EGF) family and their receptors [84, 95], insulin-like
growth factor-I (IGF-I) and IGF-I receptor [96, 97], and hepatocyte growth factor
(HGF) and the receptors, such as Met [98, 99].

HYPOTHESIS AND SPECIFIC AIMS
Several laboratories including ours reported that transcription factor Sp1 is an
important angiogenic molecule in several tumor types [61, 100-104]. Sp1 is a
zinc finger protein, and it is essential to the trans-activation of many genes that
contain GC boxes or GT boxes (also called Sp1 site) in their promoters. Sp1 has
been considered to be a basal transcription factor because of its constitutive
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expression; however increasing evidence suggests that several of biological
functions are regulated by Sp1, such as cell growth, survival, and differentiation.
These biological functions are closely related to tumor development and
progression [105, 106]. It has been reported by our lab that Sp1 over-expression
is correlated with the angiogenesis and poor prognosis of human gastric and
pancreatic cancer [60, 61, 107-109]. With these experimental evidences, I
hypothesize that transcription factor Sp1 is an effective target of antiangiogenic therapy in human pancreatic cancer. To test this hypothesis, I
propose the following specific aims:
1. Determine

the

definitive

role

of

Sp1

in

pancreatic

cancer

angiogenesis. To fulfill this aim, first whether Sp1 expression is correlated with
angiogenic phenotype in human pancreatic cancer patient will be determined by
state-to-art immunohistochemistry technique and corresponding statistics.
Second, Sp1 function in pancreatic cancer angiogenesis will be defined with both
molecular biology and cellular biology technology.
2. Design and test anti-Sp1 targeting therapy effect and Sp1 function in
the up-to-date anti-VEGF targeting therapy in human pancreatic cancer.
First, Sp1 inhibitor mithramycin function will be defined to determine whether Sp1
manipulations will improve those current regimens of pancreatic cancer therapies
in mouse model. Second is to determine VEGF neutralization monoclonal
antibody

Bevacizumab

therapy

effect

and

optimize

mithramycin

and
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Bevacizumab combination treatment in mouse model. Third, the underling
mechanism of the anti-angiogenic therapy will be explored.
3. Determine therapeutic effect of combined transcriptional repression
and protein degradation of Sp1 for treatment of pancreatic cancer in mouse
models. First is to determine the ability of mithramycin and/or tolfenamic acid to
manipulate Sp1 in vitro. Second, therapeutic effect of mithramycin and/or
tolfenamic acid will be determine on pancreatic cancer with mouse model. Third,
the corresponding molecular mechanism of the anti-Sp1 anti-angiogenesis
therapy will be explored.

In summary, this study will be to determine the definitive role of transcription
factor Sp1 in human pancreatic cancer and to design and test anti-Sp1 targeting
therapy in mouse models. The long-term goal of the study would be to translate
the therapeutic designs to clinic and benefit pancreatic cancer patients.
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CHAPTER I
Definitive Role of Sp1 in Pancreatic Cancer Angiogenesis
INTRODUCTION
PANCREATIC CANCER ANGIOGENESIS

Just like in most solid tumors, angiogenesis plays important roles in both
pancreatic tumor growth and metastasis. A range of angiogenic factors regulates
angiogenesis process [82, 88, 90]. VEGF, PDGF and bFGF were considered to
be the most important molecules among the various of angiogenic factors [82]. In
pancreatic cancer, VEGF family was the most important angiogenic factor and
has been well documented [88-90]. VEGF family has 6 members (Figure1),
VEGF or VEGF-A (located on 6p12-p21) [110], VEGF-B (located on 11q13)
[111], VEGF-C (located on 4q34) [112], VEGF-D (located on Xp22.31) [113],
VEGF-E (found in virus ) [114], and placenta growth factor (PlGF, located on
14q24-q31) that is 53% identity to the platelet-derived growth factor-like region of
VEGF-A [115]. VEGF-A is the most well-characterized member and has at least
6 isoforms. The gene coding region spans 14kb and has 8 exons (exon 6 and 7
are the membrane binding domain) [116, 117]. VEGF189 and VEGF206 anchor in
the membrane and stay in the extracellular matrix. VEGF165 (without exon 6) can
be secreted or membrane bonded. VEGF121 (without exon 6 and 7) is a free
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diffusible protein. VEGF121 and VEGF165 bind to and activate VEGFR-2 to induce
mitogenic and permeability-enhancing. Others only work on permeabilityenhancing. VEGF-B has 2 isoforms, VEGF167 and VEGF186[118]. They can all
form heterodimer with VEGF-A. VEGF-C and D are more selective growth factors
for endothelium and lymphatic vessels by binding VEGFR-3.

VEGF family members release their signal by binding VEGF receptor in the cell
surface [119]. There are 5 VEGF receptors (Figure1), 2 of them were identified
from endothelial cells first. They are the 180kDa fms-like tyrosine kinase 1 (Flt1
or VEGFR1) and the 200kDa kinase insert domain receptor (KDR or VEGFR2).
VEGFR2 binds VEGF-A, VEGF-C, VEGF-D, VEGF-E, whereas VEGFR1 binds
VEGF-A, VEGF-B and PlGF. They are expressed mainly on vascular cell of
endothelial origin. The third receptor is the 180kDa Flt4 (or VEGFR3). It binds
VEGF-C and VEGF-D. Similar to VEGFR2, VEGFR3 is mainly expressed on
endothelial cell during early development of embryo [120, 121]. However its
expression is mostly limited to lymphatic endothelial cell in the differentiated
tissues [122]. The other two receptors were the 130-140kDa isoforms Neuropilin1 (brief as NRP-1), Neuropilin-2 (brief as NRP-2). NRP-1 can bind VEGF165, and
PlGF. NRP-2 is similar to NRP-1 and can bind VEGF165, VEGF145, PlGF and
VEGF-C. NRP-1 and 2 are different from other family members [123]. They have
a short intracellular domain. The short intracellular domain cannot transduce
biological signals independently. It was considered that they may act as a coreceptor for VEGFR-1 and VEGFR-2. The interaction of ligand and receptor
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could be enhanced and the signal might be amplified by their anticipation in the
complex [123].

Studies

have

shown

that

anti-angiogenesis

therapy

inhibits

pancreatic

tumor growth in mouse model. Currently targeting VEGF signaling and function is
still a hot spot in anti-angiogenesis, tumor growth and metastasis. Strategies
have been developed, including the use of anti-VEGF antibodies, targeting VEGF
receptors to directly interfere the signal effect [124, 125]. Additionally, multiple
genes, identified in pancreatic cancer switch of the "angiogenic network" [126,
127], were also proposed to be the anti-angiogenic targets and targeted in
experimental mouse model [58, 128]. These reported results from different
experimental and

clinical

processes

with

different

approaches

showed

the importance of the angiogenic process in pancreatic cancer. Also, replication
deficient recombinant adenovirus mediated vasostatin was evaluated in human
pancreatic cancer mouse model and shown to be efficient gene therapy for
pancreatic carcinoma [129].

How the angiogenic molecules regulate angiogenesis process in pancreatic
cancer is still not clear, while it is crucial to understanding the mechanism for
designing effective anti-angiogenic therapies. Several reports including ours
indicated that Sp1 plays a key role in VEGF and angiogenesis regulation of
human pancreatic cancer [61, 130].
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Figure 1 VEGF family members and their receptors VEGF family has 6 members,
VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E (Virus protein, not shown here) and
PIGF. VEGF has 5 receptors, VEGFR-1, VEGFR-2, VEGFR-3, Neuropilin-1 and
Neuropilin-2.
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SPECIFICITY PROTEIN 1 (Sp1) AND PANCREATIC CANCER

Sp1 is a transcription factor that has three tandem zinc finger domains in its
carboxyl terminal. It was the first sequence-specific regulator of mammalian gene
transcription and was cloned by James Kadonaga in 1987 [131]. It can binds to
Sp1 sites in the early promoter of SV40 virus with the carboxyl terminal
characteristic tandem Cys2His2 ((Tyr, Phe)-Xaa-Cys-Xaa2,4-Cys-Xaa3-Phe-Xaa5Leu-Xaa2-His-Xaa3-5-His) zinc finger structure. It is believed that Sp1 can bind to
GC and GT boxes (Sp1 site) in promoter and regulates the transcription. Sp1
sites were found in numerous mammalian gene promoters. Sp1 was thought to
be responsible for recruitment of TATA-binding protein (TBP) and to fix the
transcription starting site and was considered as a basal transcription factor.

Researchers have cloned transcription factors similar to Sp1 named as Sp2, Sp3,
Sp4, Sp5, Sp6, Sp7 and Sp8 [132]. These eight molecules form the Sp multi-gen
family. They all have the characteristic three tandem zinc finger structure at
carboxyl terminal (Figure 2). Sp2, Sp3, and Sp4 also have glutamine-rich transactivation domain. But Sp2 is mainly expressed in neural system. Sp3 and Sp4
are considered to be closely related to Sp1. The tandem zinc finger structure
character is also appeared in Krüppel-like factor family. These transcription
factors may have the transcriptional activation or repression function.

Sp1 has been considered to be a basal factor since it was discovered. But more
and more experimental evidence indicated that it can regulate a variety of
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biologic functions. In cancer biology, these functions are important to tumor
development and progression [60, 108, 109, 132-134]. Recently, several studies
have reported that other Sp family members are also over-expressed in
pancreatic cancer cells. The elevated expression of these molecules was also
found in tumors compared with non-tumor tissue. These alterations play
important role in the pancreatic cancer malignance nature.

Pancreatic cancer is believed to be resulting from the genetic alternation of lots
of genes. The average of the alternation was reported to be 63 [135]. All these
alternations finally converge their signaling to a small number of transcription
factors. Sp1 is considered to be one of the several oncogenic transcription
factors and is important in pancreatic cancer pathogenesis [58, 132].
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Figure 2 Sp family members and their structures The Sp box (SPLALLAATCSR/KI)
at the N-terminus is highly conserved of the Sp proteins. It contains an endoproteolytic
cleavage site that is close to a proteasome-dependent degradation target region of Sp1
in vitro. The (Btd) Buttonhead element is important in the synergistic activation by Sp
protein with sterol-regulatory element-binding proteins. The carboxyl-terminal has the
family marker region, featuring three Cys2His2 zinc “fingers”, which are required for
sequence-specific

DNA

binding

to

GC-rich

promoter

elements.

The

(S/T)

serine/threonine-rich subregions located next to the glutamine-rich regions are believed
to be involved in post-translational modification. The (Q-rich) glutamine-rich portions of A
and B are required for trans-activation. Each of which can stimulate transcription when
tethered to DNA through a DNA-binding domain.
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MATERIAL AND METHODS
Information of Human Tissue Specimens and Patient

Specimens of human pancreatic cancer tissue from the Pancreatic Cancer
Tissue Bank (Shanghai Jiaotong University-Affiliated Ruijin Hospital) were used.
These specimens were well archived. Pancreatic tumors in these patients were
all primary pancreas tumors. Patients were diagnosed and treated at Ruijin
hospital from 2002 to 2004. All of the patients did not received pre-operative
chemotherapy or radiation therapy before surgery. 35 patients were selected to
represent all stages of pancreatic tumor. The group of studied patients consisted
of 20 men (57.1%) and 15 women (42.9%). 16 patients (45.7%) were aged > 60
years, and 19 patients (54.3%) were aged < 60 years (mean age, 60.4 years).
The tumor, lymph node, metastasis (TNM) criteria was used to staging the
patients. There are 4 patients (11.4%) had stage I disease, 26 patients (74.3%)
had stage II disease, 3 patients (8.6%) had stage III disease, and 2 patients
(5.7%) had stage IV disease.

Human Normal and Tumor Tissue Specimens Immunohistochemical
Staining

Sections (5 µm thick) of formalin-fixed, paraffin-embedded pancreatic tumor
specimens were prepared and processed for immunohistochemistry to detect
Sp1 and VEGF protein expression and tumor MVD by using anti-Sp1, anti-VEGF,
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and anti-CD34 antibodies respectively. Antigen retrieval was performed with
0.05% saponin for 30 min at room temperature. Endogenous peroxidase was
blocked using 3% hydrogen peroxide in PBS for 12 min. The specimens were
incubated for 20 min at room temperature with a protein blocking solution
consisting of PBS (pH 7.5) containing 5% normal donkey serum and bovine
serum albumin and then incubated at 4°C in polyclonal antibody against human
Sp1 (clone PEP2) or VEGF overnight. The samples were then rinsed and
incubated for 1 hour at room temperature with peroxidase conjugated anti-rabbit
IgG. Next, the slides were rinsed with PBS and incubated for 5 min with
diaminobenzidine. The sections were washed three times with distilled water,
counterstained with Mayer’s hematoxylin (Richard Allan Scientific, Kalamazoo,
MI), and washed once with distilled water and PBS. Afterward, the slides were
mounted using Universal Mount (Biomeda Corporation, Foster City, CA) and
examined using a bright-field Leica microscope.

A positive reaction was indicated by a reddish-brown precipitate. Depending on
the percentage of positive cells and staining intensity, staining was classified into
three groups: negative, weak positive and strong positive. Specifically, the
percentage of positive cells was divided into five grades (percentage scores) :
<10% (1), 10–25% (2), 25–50% (3), 50–75% (4), and >75% (5). The intensity of
staining was divided into four grades (intensity scores): no staining (1), light
brown (2), brown(3), and dark brown (4). Sp1 and VEGF staining positivity were
determined by the formula: overall scores = percentage score x intensity score.
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The tissues sections were scored by 2 independent investigators prior knowing
the patient outcomes, and the mean values of 2 independent scores are
presented [60, 130, 136].

Cell Lines Information and the Corresponding Culture Conditions

The human pancreatic adenocarcinoma cell lines AsPC-1, BxPC-3, and PANC-1
were purchased from the American Type Culture Collection (Manassas, VA). FG
human pancreatic adenocarcinoma cells were established by Vezeridis et al
[137]. All of the cell lines were maintained in plastic flasks as adherent monolayer
in minimum essential medium supplemented with 10% fetal bovine serum,
sodium pyruvate, nonessential amino acids, L-glutamine, and a vitamin solution
(Flow Laboratories, Rockville, MD). Human umbilical vein endothelial cells
(HUVECs) were purchased from BD Biosciences (San Jose, CA) and were
cultured with the endothelial cell culture medium (BD Biosciences, San Jose, CA)
according to the manufacturer’s instructions.

Small-interfering RNA Information

Small interfering RNA (siRNA) reagents, including transfection reagents, were
obtained from Invitrogen (Carlsbad, CA). A Sp1 Stealth RNAi duplex oligo was
used to knock down Sp1 expression in pancreatic cancer cells. Non-targeting
scrambled Stealth RNAi Negative Control siRNA were used as negative controls

21

according to the manufacturer's instructions. In vitro transfection was performed
by using Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA).

Animals Information and Animal Care

Female athymic nude mice and C57BL/6 mice were purchased from Jackson
Laboratory (Bar Harbor, ME). The mice were housed in laminar flow cabinets
under specific pathogen-free conditions and were used when they were 8 weeks
old. The animals were maintained in facilities approved by the Association for
Assessment and Accreditation of Laboratory Animal Care in accordance with the
current regulations and standards of the U.S. Department of Agriculture,
Department of Health and Human Services, and National Institutes of Health in M
D Anderson Cancer Center animal facility.

Animal Models of Tumor Growth and Metastasis
Tumor cells (1 × 106 cells per mouse) were injected into the subcutis or pancreas
of nude mice in groups of 5 to 10 mice. The animals were killed 60 days after the
tumor-cell injection or when they had become moribund. Next, their primary
pancreatic tumors were harvested and weighed. In addition, the liver from each
mouse was removed and fixed in Bouin solution (BBC Biochemical, Dallas, TX)
for 24 hours to differentiate the neoplastic lesions from the organ parenchyma;
metastases on the surface of the liver were counted under a dissecting
microscope.
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Western Blot Protocol

Whole-cell lysates of human pancreatic cancer cell lines or tissues were
prepared [61]. Standard Western blot analyses were performed by using
corresponding antibodies and the anti-rabbit immunoglobulin G (IgG) antibody, a
horseradish

peroxidase–linked

F(ab')2

fragment

obtained

from

donkey

(Amersham, Arlington Heights, IL) as probing molecule. Equal protein-sample
loading was monitored by probing the same membrane filters with an antiglyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody [61]. The probe
proteins were detected by using the Amersham enhanced chemi-luminescence
system according to the manufacturer's instructions.

Immunohistochemical Staining of Human Pancreatic Tumor Xenograft
Specimens

For VEGF and Sp1 staining of human pancreatic xenograft specimens, sections
(5 µm thick) from formalin-fixed, paraffin-embedded pancreatic tumor specimen
were de-paraffinized in xylene and rehydrated in graded alcohol. For CD31
staining, frozen sections (6 µm thick) of tumor specimens were fixed with acetone.
Sp1 and VEGF expression and MVD status in the sections were assessed as
described previously.

Matrigel Plug Assay
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Matrigel (200 µl) containing 2 × 106 cells of different treated pancreatic cancer
cells described above was injected subcutaneously into nude mice (2 injection
sites per mouse). The Matrigel plugs were recovered from the mice 10 days after
injection and carefully stripped of host tissues [138-142]. After photography, the
Matrigel plugs were weighed and homogenized in 1 ml of distilled water and then
centrifuged at 10,000 revolutions per minute for 5 minutes. The supernatants
were collected for hemoglobin measurement using Drabkin solution (SigmaAldrich, Saint Louis, CA) and measured with a Spectra Max M5 Microplate
Manager enzyme-linked immunosorbent assay reader at 540 nm according to
the manufacturer's instructions. The relative hemoglobin concentrations were
calculated and further normalized according to the weights of the plugs.

Endothelial Cell Tube Formation Assay

A standard tube formation assay was performed using human umbilical vein
endothelial cells (HUVECs) [138, 141]. PANC-1 cells (3 × 106) of deferent
treatments were cultured in 1 ml of serum-free medium for 24 hours, and the
medium was collected and centrifuged to remove any cell debris before its use
as a conditional medium. HUVECs were cultured with endothelial cell culture
medium (BD Biosciences, San Jose, CA). 24-well plates were coated with
reconstituted

Matrigel

(BD

Biosciences,

San

Jose,

CA)

following

the

manufacturer’s directions. 2 x 104 HUVECs were transferred to each well of 24well plates and incubated in culture medium at 37°C, 5% CO2 for adhesion. Then
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culture medium was replaced with the conditional medium harvested from
different treated cells and incubated for 18 hours [143]. The degree of tube
formation was assessed as the percentage of cell surface area versus total
surface area. Pictures were captured with bright-field Leica microscopy using a
Spot-RT digital camera equipped with a Spot Imaging 4.7 program.

Statistical Analysis

For studies using human specimens, the chi-square test was performed to
determine the significance of the differences between the covariates (Sp1, VEGF,
and MVD). For in vitro and in vivo studies, each experiment was performed
independently at least twice with similar results; 1 representative experiment is
presented. The significance of the in vitro data was determined using the Student
t test (two-tailed), whereas the significance of the in vivo data was determined by
using the Mann-Whitney U test. P < 0.05 was deemed significant.
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RESULTS
Correlation of Sp1 expression levels with VEGF expression and MVD in
human pancreatic cancer patients specimen

Researchers have reported the importance of Sp1 in pancreatic cancer and that
the expression of VEGF, one of the most key angiogenic molecules, depends on
Sp1, which have suggested the role of angiogenesis in pancreatic cancer. But
studies have not yet investigated the relation between MVD status, one of the
angiogenic index, VEGF expression and Sp1 expression. The underlying
interaction between these 3 factors in pancreatic cancer is not clear.

To answer this important question, 35 primary pancreatic cancer tissue
specimens were used to evaluate Sp1, VEGF expression and MVD status using
immunohistochemistry staining and corresponding statistics. It was found that the
MVD status was correlated highly with Sp1 expression (P < 0.001) (Fig. 3A1).
The level of Sp1 expression was correlated significantly with VEGF expression
level (P < 0.05) (Fig. 3A2).

These co-relationships were confirmed by analyzing the consecutive sections of
human pancreatic cancer specimens. The representative immunohistochemistry
staining pictures of two representative patients’ specimens (selected from those
35 patients) were shown in Figure 4. The patient that has strong Sp1 expression
(Fig. 4A1) has high MVD (Fig. 4A2), while the patient that has very weak Sp1
expression (Fig. 4B1) has low MVD and very small micro vessel (Fig. 4B2).
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Obviously the pattern of Sp1 expression was consistent with MVD status.
Therefore, it can be concluded that Sp1 can regulate human pancreatic cancer
angiogenesis with the supportiveness of these clinical evidence shown in Figure
3 and Figure 4.
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Figure 3 the level of transcription factor Sp1 expression correlates with the
microvessel density (MVD) status in human pancreatic cancer. (A) Tissue sections
were prepared from formalin-fixed, paraffin-embedded pancreatic tumors (35 patients).
Immunohistochemical staining was performed by using specific antibodies against Sp1,
vascular endothelial growth factor (VEGF), and CD34 (MVD) and was scored as
described in Material and Methods. The direct correlations between Sp1 expression and
MVD status (A1) (P < 0.001) and between Sp1 expression and VEGF expression (A2) (P
< 0.05) were analyzed using the Person chi-square test.
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Figure 4 Representative immunohistochemistry staining results.. Two sets of
consecutive tissue sections that were positive ((A1) and negative (B1)
1) for Sp1 expression
also were stained for CD34 expression ((A2, B2).
2). Representative photomicrographs are
shown (original magnification, ×100). It is noteworthy that Sp1 expression correlated
directly with MVD status.
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Sp1 expression were specifically knockdown in human pancreatic cancer
cells

Several pancreatic cancer cell lines, including AsPC-1, BxPC3, FG and PANC-1
were transfected with Sp1 small-interfering RNA (si-Sp1) or control siRNA
duplexes (si-Ctr) using Lipofectamine 2000 according the direction from
Invitrogen (Carlsbad, CA). Cells were harvested after 24 hours of treatment to
prepare whole cell lysates. Western blot was used to analyze protein level
changes.

Sp1 expression down-regulation was confirmed in these cells (Fig. 5A). Sp1
protein was knockdown to less than 10% and even near 0% in particular cell line
like PANC-1. In Sp1 protein family, Sp3 and Sp4 are close to Sp1. The specificity
of Sp1 knockdown but not Sp3 or Sp4 was confirmed with Western Blot and the
quantitative result was shown (Fig. 5B).

The specificity of Sp1 knockdown in different species was also determined with
tumor cell lines from human and mouse. Mouse melanoma cell line B16 and
pancreatic tumor cell line H7 were selected. The specificity was confirmed with
Western Blot (Fig. 6A). The siRNA targeting sequence is also listed and there is
only one nuclear acid unmatched with mouse sequence (Fig. 6B). But the mouse
Sp1 protein level has no change in comparison with human Sp1.
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Figure 5 Knockdown of transcription factor Sp1 expression. For Sp1 knockdown,
AsPC-1, BxPC-3, FG, and PANC-1 cells were transfected with Sp1 small-interfering
RNA (si-Sp1) or with control small-interfering RNA (si-Ctr). Sp1 expression in these cells
was confirmed by using Western blot analysis (A). PBS indicates phosphate-buffered
saline; NS, nonspecific bands. The specificity of Sp1 knockdown in Sp protein of these
cells was confirmed by using Western blot analysis and was quantitated (B).
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Figure 6 Specificity of knockdown of transcription factor Sp1 expression. Human
pancreatic cell line PANC-1, mouse melanoma cell line B16 and pancreatic cell line H7
were transfected with Sp1 small-interfering RNA (si-Sp1) or with control small-interfering
RNA (si-Ctr). Sp1 expression in these cells was confirmed by using Western blot
analysis (A). PBS indicates phosphate-buffered saline; NS, nonspecific bands. The
siRNA target sequence and the corresponding regions of human and mouse were
shown (B). The only unmatched nuclear acid was marked in red.
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Human pancreatic cancer cells lost the angiogenic potential after Sp1
expression were knockdown

To determine the Sp1 function in pancreatic cancer angiogenesis, tube-formation
and Matrigel plug assay were performed as described in Material and Methods.

Briefly, PANC-1 cells were transfected with control, si-Ctr or si-Sp1. The
angiogenic potential of the supernatants of PANC-1 cells was determined using
an endothelial cell tube formation assay following the protocol provided by
supplier. The degree of tube formation was assessed as the percentage of cell
surface area versus the total surface area and the statistic result was shown (Fig.
7A). Representative photomicrographs of different treatment groups were taken
in situ for tube formation of HUVECs incubated in the supernatants of different
treatment groups (Fig. 7B). As it shown that PANC-1 cells transfected with si-Sp1
reduced the capacity of its supernatant’s stimulate tube formation of endothelial
cells when comparing with the capacity of supernatants of PANC-1 cells
transfected with si-Ctr.

The expression of several genes was analyzed after Sp1 knockdown with
Western Blot (Fig. 8A). As it revealed that the expression of EGFR, PDGF, and
VEGF were down regulated. These are consistent with other researchers’
reports. Sp1 sites in the promoter region of these angiogenic growth factors are
the key regions to regulate their mRNA synthesis.
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To further determine Sp1 knockdown effect on pancreatic cancer cell
angiogenesis, Matrigel plug assay was performed according to Material and
Methods. The angiogenic potential of pancreatic cancer cells was impaired in
vivo (Fig. 8B). The data suggested that the knockdown Sp1 protein expression
impaired the angiogenic potential of pancreatic cancer cells.
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Figure 7 Human pancreatic cancer cells lost the angiogenic potential after
knockdown of transcription factor Sp1 expression in vitro. The angiogenic potential
of the supernatants of PANC-1 cells, PANC-1 cells transfected with si-Ctr, and PANC-1
cells transfected with si-Sp1 was determined by using an endothelial cell tube formation
assay (A). Representative photomicrographs were taken in situ of human umbilical vein
endothelial cell tube formations in the supernatants of PANC-1 cells treated with si-Ctr or
si-Sp1 (B). * P < 0.05 in a comparison between the treated and respective control
groups.
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Figure 8 Knockdown of transcription factor Sp1 expression attenuates human
pancreatic cancer cell angiogenic potential in vivo and gene expression analyses
in vitro. PANC-1 cells were treated as described above, and total protein lysates were
prepared. Western blot was used to analyze vascular endothelial growth factor (VEGF),
epidermal growth factor receptor (EGFR), and platelet-derived growth factor (PDGF)
protein by using corresponding specific antibodies (A). For Matrigel plug assay, Matrigel
(500 µL) that contained 2 × 106 PANC-1 cells or PANC-1 cells treated with si-Ctr or siSp1 was used as described in Materials and Methods (B) (Hb indicates hemoglobin). It
is noteworthy that the down-regulation of Sp1 expression impaired the angiogenic
potential of pancreatic cancer cells in vitro and in vivo. * P < 0.05 in a comparison
between the treated and respective control groups.
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Knockdown of Sp1 expression suppressed human pancreatic cancer cells
growth in vivo and correlated with impaired angiogenesis

To determine whether cell cycle was affected after knockdown Sp1 expression in
vitro, MTT assay and FACs analysis were performed as described in Material
and Methods.

Briefly, BxPC-3, FG, and PANC-1 cells were incubated in medium alone or in
medium that contained Lipofectamine with si-Ctr or si-Sp1 for 3 days. 3-(4, 5dimethiazol-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) assay was
used to assess the cell growth (Fig. 9A1). The viable cells that can be stained by
trypan blue were counted (Fig. 9A2). The level of cell cycle progression was
determined by using fluorescence-activated cell sorter analysis with propidium
iodide staining (Fig. 9B). It was observed that the difference of S + G2 + M phase
cells was about 2 percent. Knockdown Sp1 protein expression had minimal effect
on tumor cell growth in vitro.

Whether knockdown of Sp1 expression affects tumor growth in vivo was then
determined. FG or PANC-1 cells transfected with si-Ctr or si-Sp1 were injected
into the pancreas of mice. Mock transfected cells were also used as control. 10
mice were used for each treatment group. Mice were sacrificed at the end of
second month after the injection. Tumors were harvested and weighted for
extended analysis.
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When assessed by tumor weight, it was found that FG or PANC-1 cells
transfected with si-Ctr produced larger tumors. But the cells transfected with siSp1 produced smaller tumors (Fig. 10A). The MVD status of xenograft tumor
tissue specimens was processed and photomicrographed as described in
Material and Methods. Representative pictures of each treatment group from
PANC-1 xerograph tumor were shown (Fig. 10B). It is clearly showed that,
PANC-1 cells transfected with si-Sp1 formed tumors had less vascular than
those formed by cells transfected with si-Ctr or mock transfection.
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Figure 9 Knockdown of transcription factor Sp1 expression does not affect the in
vitro growth of human pancreatic cancer cells. (A) BxPC-3, FG, and PANC-1 cells
were treated for 3 days as described in the legend to Figure 4, and viable cells were
determined using an 3-(4,5-dimethiazol-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide
(MTT) assay (A1). PANC-1 cells were treated for 1 to 5 days as described in the legend
to Figure 5, and viable cells were determined by viable cell counting (A2) PBS indicates
phosphate-buffered saline; si-Ctr, control small-interfering RNA; si-Sp1, Sp1 smallinterfering RNA. (B) PANC-1 cells were treated with PBS (B1), si-Ctr (B2), or si-Sp1 (B3)
for 48 hours as described in the legend to Figure 4. Cells were stained with propidium
iodide and were subjected to fluorescence-activated cell sorter analysis. Percentages in
M1 (G1), M2 (G2/M), M3 (S), and M4 (apoptosis) are calculated. This was 1
representative experiment of 2 that produced similar results.

39

Figure 10 Knockdown of transcription factor Sp1 expression effectively attenuates
the in vivo angiogenic potential and growth of human pancreatic cancer. FG or
PANC-1 cells, FG or PANC-1 cells transfected with control small-interfering RNA (si-Ctr),
and FG or PANC-1 cells transfected with Sp1 small-interfering RNA (si-Sp1) were
injected into the pancreas of mice (n = 5). (A) Primary pancreatic tumors were weighed
(A1, A2) PBS indicates phosphate-buffered saline. (B) The microvessel density status of
PANC-1 pancreatic tumors formed by PANC-1 cells (B1), PANC-1 cells transfected with
si-Ctr (B2), and PANC-1 cells transfected with si-Sp1 (B3) was determined by using
CD31 staining. * P < 0.05 in a comparison between the treated and respective control
groups.
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To summarize the results, Sp1 expression correlated with VEGF expression and
MVD in pancreatic tumor patient specimen. Sp1 protein can be knocked down
specifically by using Sp1 specific siRNA oligo. Knockdown Sp1 expression in
human pancreatic cancer cells leads to their losing of angiogenic potential. All
the experimental results indicated that Sp1 has a key function in pancreatic
cancer angiogenesis.

41

DISSCUSSION
In this chapter, evidence from clinic and experiment were provided to show that
transcription factor Sp1 is an important regulator of human pancreatic cancer
angiogenesis. Especially, the Sp1 protein expression level was correlated directly
with VEGF expression level and MVD status in human pancreatic cancer.
Specifically knockdown human Sp1 expression led to the inhibition of pancreatic
cancer angiogenesis and tumor growth in vivo. In addition, the anti-angiogenic
activity of knock down Sp1 directly resulted in the down-regulation of Sp1
downstream pro-angiogenic molecules VEGF, PDGF, and EGFR. The
experimental results provided strong and important evidence to support the point
that Sp1 is the key angiogenic regulator in human pancreatic cancer and would
have significant implications in pushing the understanding of pancreatic cancer
angiogenesis and important directional logical designing of effective antiangiogenesis therapies for the disease.

As it has been discussed previously, angiogenesis has important role in both the
maintaining of growth and metastasis pancreatic cancer. Both scientific
researchers and clinicians have more and more interest in pancreatic cancer
angiogenesis. The anti-angiogenic therapy is becoming a hot field and more
scientific research results were translated to pre-clinic and clinic processes.
Studies have demonstrated that anti-angiogenic therapies suppress tumor
growth in pancreatic cancer mouse models [130, 144-147]. It has becoming
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wildly recognized that human pancreatic cancer has elevated angiogenesis in
which a distorted local balance of multiple pro-angiogenic and anti-angiogenic
factors is involved [58, 84, 86, 87, 148, 149]. The imbalance is the predomination
of angiogenic factors over angiogenic inhibitors. Among the growing list of
angiogenic factors, all of the VEGF isoforms were reported to be important for
the pancreatic tumor growth and metastasis [58, 84]. Additionally, other
angiogenic factors are also over expressed in pancreatic cancer cells, such as
EGF, HGF, TGFα, PDGF, FGFs (FGF-1, FGF-2, and FGF-5) and platelet-derived
endothelial cell growth factor. The K-ras mutations and over-expression of HIF1α, thrombospondin-1, thymidine phosphorylase, and cathepsins B and L [58, 84]
are also important contributing factors. Studies have demonstrated that
expression of these factors or the combination of these factors or the
combinations of them with other factors correlated with elevated vascular
formation. The poor prognosis of pancreatic cancer patients under these
pathological situations was also reported [58, 84]. Interference of the expression
and the substance function of these factors have significant influences on
angiogenesis and xenograft pancreatic tumor growth in mouse models [124, 150].
However simultaneously manipulating several target molecules remains a big
challenge in clinic.

It has been demonstrated that Sp1 is constitutive activated in pancreatic cancer
cells. The constitutive Sp1 activity is essential for constitutive, inducible VEGF
expression [58, 61, 88, 108, 134, 151]. The current experimental results
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demonstrated that over-expression of Sp1 is correlated with MVD status in
human pancreatic cancer tissue. Knockdown Sp1 protein expression with the
siRNA oligo significantly inhibits the tumor angiogenic potential. The Sp1
expression knocking down produced anti-angiogenic effect. That is consistent
with down-regulated expression of several angiogenic signaling molecules by
knockdown Sp1 expression. These molecules are in the signaling pathways that
can regulate pancreatic cancer angiogenesis [60, 108, 109]. All these
experimental results suggested that the transcriptional regulation is the
underlying mechanism of over-expression of various angiogenic factors that
collectively regulate pancreatic cancer angiogenesis [58, 88, 150].

The current study had also demonstrated that knockdown of Sp1 expression
significantly reduced the angiogenic potential of human pancreatic cancer cells in
vitro and led to the angiogenic phenotypic change in vivo. All of the evidence
indicates that Sp1 plays an important role in pancreatic cancer angiogenesis
regulation.
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CHAPTER II
Mithramycin Based Anti-angiogenic Therapy of Pancreatic
Cancer in Mouse Model
INTRODUCTION
HUMAN PANCREATIC CANCER THERAPEUTICS

In the past twenty to thirty years, pancreatic cancer patients’ cases have
increased greatly. It is ranked as the fourth leading cause of cancer related death
in the North America currently. Pancreatic cancer has a high case: fatality ratio
and the etiology are still poorly explored although various approaches have been
used to identify its origin [152]. Pancreas cancer patient is almost incurable. The
overall survival (OS) rate is less than 4% [153]. If the tumor is detected in
resectable localization and period, it has highly curable ratio. However,
pancreatic cancer patients found in the stage are less than 20%. Recently
medical imaging technology, such as positron emission tomographic (PET) scans,
magnetic resonance imaging (MRI) scans, high resolution endoscopic ultrasound
examination, and spiral computed tomographic (CT) scans has been improved.
Together with the improving prevention, the pancreatic cancer diagnosis has
been moving forward.
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Besides the remaining problem of its diagnosis, pancreatic cancer is highly
resistant to chemotherapy and radiation therapy. Surgery resection is still the
primary choice when it is feasible [154-156]. There has been conflicting results
reported by different researches on postoperative therapy. The management of
patients after surgery remains to be another important question to be answered
[157-159].

Currently, it is urgent to identify new targets for treating pancreatic cancer
patients effectively. To fulfill the task, it is important to understand pancreatic
cancer development and progression. There are average sixty three genetic
alternations in pancreatic cancer patient. All of these genes that regulate
angiogenesis, growth, and metastasis could be the potential targets [84, 85, 155157, 160-162]. Vascular endothelial growth factor (VEGF), basic fibroblast growth
factor (bFGF) and platelet-derived growth factor (PDGF) were considered to be
the most important angiogenic factors. In pancreatic cancer epidermal growth
factor (EGF) and its receptor (EGFR), insulin-like growth factor I (IGF-I) and its
receptor, hepatocyte growth factor and its receptor Met were also considered to
be important to angiogenesis [58, 84, 163]. Pancreatic cancer angiogenesis is
correlated with these of angiogenic factors’ expression. Over-expression of
VEGF has been reported to be correlated with microvessel density (MVD) in
human pancreatic cancer. In mouse model VEGF-targeting therapy inhibited
angiogenesis and tumor growth of pancreatic cancer [58, 84, 163]. But how these
angiogenic factors could be up-regulated is to be determined [58, 84].
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Not only our lab but also other group reported that VEGF expression was
regulated by Sp1 in pancreatic cancer [61, 130, 151]. With the importance of
VEGF in angiogenesis of pancreatic cancer, Sp1 could be an anti-angiogenic
target in the treatment. Besides this, the role of Sp1 in anti-angiogenic
therapeutic treatments is also to be determined. Detailed mechanism studies of
these treatments would provide better understanding to the clinical outcomes.
Pancreatic cancer treatment regimen might be developed systematically and
specifically.

MITHRAMYCIN

Mithramycin is an aureolic acid antibiotic that is produced by a genus of bacteria
Streptomyces sp [164, 165]. Most of the commercial available mithramycin is
purified from Streptomyces argillaceus. In the past, it was mainly used to treat
hypercalcemia, the high calcium level in blood or urine, in patients with bone
metastases [166, 167]. Physicians also used it in treatment of Paget disease,
testicular carcinoma and leukemia [168-173]. Recently, it was reported that
mithramycin might be a potential neuroprotective drug in Huntington’s disease
treatment [174].

Mithramycin is believed to bind to GC-rich regions in DNA and thus regulates the
transcription of the downstream genes [175]. Mechanistically two mithramycin
molecules bind to DNA sequence with GC-base specificity. The binding is
coordinated by a divalent cation, such as magnesium or zinc ion, and is believed
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to be a reversible process [176]. Recently, it was reported that mithramycin
stimulated tumor necrosis factor-alpha-related apoptosis-inducing ligand, Fas
ligand and tumor necrosis factor induced apoptosis in tumor cells and prevented
p53-mediated transcriptional activation [177-180]. The major mechanism of
mithramycin, including anti-tumor activity, is believed to inhibit Sp1 binding
activity.

BEVACIZUMAB

Living cells constantly need oxygen and nutrients to maintain the metabolism.
More blood supply is needed by tumor cells comparing with normal cells for
maintaining their higher proliferation rate [84, 181, 182]. During the tumor growth,
tumor cells produce growth factors to activate angiogenesis process to trigger the
formation of new blood vessels from the existing vessel. There are lots of growth
factors that were demonstrated to activate this progress. Vascular endothelial
growth factor (VEGF) was believed to be one of the most potent molecules for
the growth of pancreatic tumor [116, 117]. Besides this, it was also demonstrated
that VEGF promotes microvessel formation around tumor [116]. Moreover, it can
also increase the blood vessel permeability to provide more nutrients for tumor
cells growth and metastasis [117].

Bevacizumab (Avastin™) was developed and marketed by Genentech. It is
believed that Bevacizumab neutralizes soluble VEGF to inhibit new blood vessel
formation and causes the destruction of the existing vessels [89, 183]. Thus the
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blood supply to tumor cells would be blocked and tumor cells growth would slow
down. Bevacizumab was approved by U.S. Food and Drug Administration (FDA)
in 2004. It is the first approved biological therapy drug for combination
chemotherapy in several types of tumors. Under the instruction of National
Institutes of Health, Genentech cooperated with the National Cancer Institute
(NCI) to develop of clinical practice of Bevacizumab in cancer treatment.
Bevacizumab is humanized murine monoclonal antibody that binds to and
inhibits VEGF [89]. A monoclonal antibody is a targeting protein produced by
hybridoma.

Use Sp1 as a potential anti-angiogenic target for effective targeting therapy in
pancreatic cancer and its role in anti-angiogenic drug currently in clinic trial have
not been explored till then. In this chapter, I sought to determine whether
mithramycin has any effect on pancreatic cancer angiogenesis and if so, what
the corresponding molecular mechanism is.
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MATERIAL AND METHODS
Chemicals and Reagents Information

Mithramycin (1 mg per vial crystal powder) was purchased from Sigma Chemical
Co (St. Louis, MO). It was dissolved in sterile water and diluted for actual use.
Bevacizumab (25 mg/ml) was purchased from Genentech, Inc. For animal
experiments, mithramycin (0.1–0.4 mg/kg body weight) and Bevacizumab (25–
100 µg per mouse) were given by i.p. injection twice a week or as indicated
otherwise.

Animals Information and Animal Care

Female athymic BALB/c nude mice were purchased from The Jackson
Laboratory. The mice were housed in laminar flow cabinets under specific
pathogen-free conditions and used when they were 8 weeks old. The animals
were maintained in M D Anderson Cancer Center animal facility approved by the
Association for Assessment and Accreditation of Laboratory Animal Care in
accordance with the current regulations and standards of the U.S. Department of
Agriculture, U.S. Department of Health and Human Services, and NIH.

Cell Lines and Culture Conditions Information

The human pancreatic adenocarcinoma cell lines PANC-1 and BxPC3 were
purchased from the American Type Culture Collection (Manassas, VA). FG
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human pancreatic adenocarcinoma cells were established by Vezeridis et al
[137]. The cell lines were maintained in plastic flasks as adherent monolayers in
MEM supplemented with 10% fetal bovine serum, sodium pyruvate, nonessential
amino acids, L-glutamine, and a vitamin solution (Flow Laboratories).

Immunohistochemical Analysis and Tumor MVD Quantification Protocols

For CD31 staining, frozen tissue sections (5 µm thick) were fixed in acetone.
Endogenous peroxidase in the specimens was blocked using 3% hydrogen
peroxide in PBS for 12 min. The specimens were incubated for 20 min at room
temperature in a protein-blocking solution consisting of PBS (pH, 7.5) containing
5% normal horse serum and 1% normal goat serum and then incubated overnight
at 4°C in a 1:100 dilution of monoclonal goat anti-CD31 (PECAM1-M20),
polyclonal rabbit anti-Sp1, or polyclonal rabbit anti-VEGF antibodies (Santa Cruz
Biotechnology). The specimens were then rinsed and incubated with peroxidaseconjugated anti-goat or anti-rabbit IgG for 1 hour at room temperature. Next,
slides were rinsed with PBS and incubated with diaminobenzidine (Research
Genetics) for 5 min. Frozen sections of the specimens were then washed twice
with distilled water, counterstained with Mayer's hematoxylin (Biogenex
Laboratories), and washed once each with distilled water and PBS. Sections
were mounted on the slides using Universal Mount (Research Genetics), and the
slides were examined under a bright-field microscope. A CD31-positive, Sp1positive reaction was indicated by a reddish-brown precipitate in the cytoplasm or
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nuclei, respectively. For quantification of tumor MVD, vessels on each section
were counted in five high-power fields (magnification, x200 [x20 objective and
x10 ocular]) as described previously [184].

Western Blot Analysis Protocol

Whole-cell lysates were prepared from human pancreatic cancer cell lines and
tissues [174]. Standard Western blotting was done using polyclonal rabbit
antibodies against human and mouse Sp1, VEGF, PDGF and EGFR (Santa Cruz
Biotechnology) and the anti-rabbit immunoglobulin G (IgG) antibody, a
horseradish peroxidase–linked F(ab')2 fragment obtained from a donkey
(Amersham). Equal protein-sample loading was monitored by probing the same
membrane filter with antibodies against anti–β-actin or glyceraldehyde-3phosphate dehydrogenase (GAPDH) [60]. The probe proteins were detected
using the Amersham enhanced chemo-luminescence system according to the
manufacturer's instructions.

Sp1 Promoter Constructs Information and Analysis of Sp1 Promoter
Activity with Luciferase Assay

The minimal Sp1 promoter reporters in pGL3 luciferase constructs were
generated and used as described previously [59, 61]. In order to examine the
transcriptional regulation of the Sp1 promoters by Bevacizumab and mithramycin,
PANC-1 cells were seeded to about 80% confluence in six-well plates (in
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triplicate) and transiently transfected with 0.6 µg of minimum Sp1 reporter
plasmids and 0.3 µg of effectors expression plasmids as indicated in each
experiment using Lipofectamine (Invitrogen) according to the manufacturer's
instructions. The reporter luciferase activity was measured 48 hours later using a
luciferase assay kit (Promega). Promoter activity was normalized according to the
protein concentration as described previously [59].

Chromatin Immunoprecipitation Protocol

Chromatin was prepared from cells and tumors as described previously [59].
Chromatin immunoprecipitation (ChIP) assay was done using the Chromatin
Immunoprecipitation Assay Kit (Upstate Cell Signaling Solutions) according to the
manufacturer's instructions. Briefly, DNA cross-binding proteins were cross-linked
with DNA and lysed in SDS lysis buffer. The lysate was sonicated to shear DNA
to 200 to 500 bp. After pre-clearing with a salmon sperm DNA/protein A agarose–
50% slurry for 30 min at 4°C, chromatin samples were immunoprecipitate d
overnight with no antibody or an anti-Sp1 antibody (PEP2). The region between –
224 and –53 bp of the Sp1 promoter was amplified using the following primers:
sense, 5'-caggcacgcaacttagtc-3', and antisense, 5'-gtaaggaggagggagcag-3'. PCR
products were separated on a 1.5% agarose gel, stained with ethidium bromide,
and visualized under UV light.

Statistical analysis
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Each experiment was done independently at least twice with similar results; one
representative experiment is presented. The significance of the in vitro data was
determined using Student's t test (two-tailed), whereas the significance of the in
vivo data was determined using the two-tailed Mann-Whitney U test. For the in
vivo experiments, the overall survival duration was calculated using the KaplanMeier method. The log-rank test was used to compare the survival duration
between groups. P < 0.05 was deemed significant.
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RESULTS
PART 1. MITHRAMYCIN TREATMENT ON HUMAN PANCREATIC CANCER
ANGIOGENESIS
Mithramycin treatment inhibits human pancreatic tumor growth in
xenograft mouse models

As it was introduced, mithramycin, as a Sp1 inhibitor, can inhibit Sp1 protein
expression and interpose Sp1 recruitment to Sp1 sites. But whether it can inhibit
pancreatic tumor growth in vivo is still unknown.

First, a set of dose-response experiments was performed. BxPC-3 cells were
injected subcutaneously into nude mice. When the tumors reached 4 mm in
diameter, animals were given mithramycin in different doses (0.1, 0.2, and 0.4
mg/kg) via intraperitoneal injection twice weekly. PBS was injected into a group
of animals that used as controls. It was observed that treatment with mithramycin
produced dose-dependent antitumor activity (Fig. 11).
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Figure 11 Dose-dependent antitumor effects of mithramycin in xenograft models
of human pancreatic cancer. BxPC3 cells were injected into the subcutis of nude mice
(n = 5). When tumors reached around 4 mm in diameter, the animals received different
doses of mithramycin [0.10 (M-10), 0.20 (M-20), and 0.40 (M-40) mg/kg] via i.p. injection
twice a week. Tumors were measured once every week, and at each measurement, the
mean ± SD tumor volume in the five mice in each group was calculated. The control
mice and mice that received mithramycin were weighed at the time of experiment
termination. Columns, mean weights; bars, SD. * P < 0.01 in a comparison between the
treated and respective control groups
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Then I sought to determine whether different administer and slow release of
mithramycin would have the same effect on xenograft tumors. BxPC3 cells were
inoculated to mice subcutis. When the tumors reached 4 mm in diameter, the
animals were gave different doses of mithramycin (0.12 mg/kg, 0.25 mg/kg, and
0.50 mg/kg) by subcutaneous or intraperitoneal injection twice weekly. It was
observed that mithramycin treatment by intraperitoneal and subcutaneous
administration can both produce dose-dependent antitumor activity (Fig. 12A).

Next, similar experiments were performed using orthotopic mouse models.
Pancreatic xenograft tumors were formed in mice pancreas as described in
Material and Methods. Same dose and frequency of mithramycin were
administered. It was found that treatment with mithramycin (0.25 mg/kg by
intraperitoneal and subcutaneous administration) significantly inhibited the
growth of BxPC-3, FG, and PANC-1 formed tumors (Fig. 12B).

Furthermore, a histopathology examination was performed using pancreatic
tumor specimens that were obtained from control mice and from mice that
received low doses of mithramycin, because no tumors formed in mice that
received high doses of mithramycin. Significant inhibition of Sp1 expression in
tumor specimens from mice that received mithramycin compared with the control
mice was observed (Fig. 12C), which was consistent with reduced MVD (Fig.
12D).
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Figure 12 Suppression of human pancreatic cancer growth by mithramycin in
xenograft models (A) BxPC-3 cells were injected into the subcutis of groups of mice (n
= 5 each). When tumors reached approximately 4 mm in greatest dimension, animals
received injections of PBS or mithramycin (0.12 mg/kg, 0.25 mg/kg, and 0.50 mg/kg)
subcutaneously (s.c.) or intraperitoneally (i.p.) twice weekly. The tumors were measured
once weekly; and, at each measurement, the mean ± standard deviation tumor volume
was calculated in each group of mice. (B) BxPC-3, FG, and PANC-1 cells were injected
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into the pancreas of mice (n = 5). Two weeks after tumor injection (when tumors
measured approximately 4 mm in greatest dimension), mice received i.p. or s.c.
injections of mithramycin (0.25 mg/kg) twice weekly. PBS injection was used as a
control. The resulting primary pancreatic tumors were weighed 45 days after the
injection. (C) Sp1 expression was determined in PANC-1 tumor tissues collected from
mice that received treatments with PBS (C1), mithramycin i.p. (C2), or mithramycin s.c.
(C3) using immunohistochemistry. (D) Microvessel density status was assessed in
PANC-1 tumor tissues collected from mice that received treatment with PBS (D1),
mithramycin i.p. (D2), or mithramycin s.c. (D3) by using CD34 staining. This was 1
representative experiment of 2 that produced similar results. * P < 0.05 in a comparison
between the treated and respective control groups.
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Gene expression analysis of mithramycin treated tumors

Because mithramycin treatment produced dose-dependent tumor growth
inhibition effect, I then sought to determine which potential angiogenic molecules
were also affected in addition to Sp1, which were related to the anti-angiogenic
effect.

Western blot analysis was performed using total protein lysates extracted from
the PANC-1 tumor tissue specimens that collected from mice that received
treatment with PBS or mithramycin. Mithramycin suppressed the expression of
Sp1 and its downstream molecules VEGF, EGFR, and PDGF (Fig. 13A), which
was consistent with reduced MVD. It is noteworthy that the expression of Sp1 in
normal tissues, including the liver, was not suppressed significantly (Fig. 13B).

The results of this part suggested that mithramycin preferentially inhibits Sp1
expression in growing tumors and has potent anti-pancreatic cancer activity. It
was demonstrated that treatment with mithramycin inhibits Sp1 expression and
down-regulates the downstream targets that are key to the angiogenesis of
human pancreatic cancer as the consequence.
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Figure 13 Preferential inhibition of transcription factor Sp1 expression in growing
pancreatic tumors and anti
anti-angiogenic effects. When BXPC-3 tumors reached
approximately 4 mm in greatest dimension, the animals received 2 subcutaneous (s.c.)
injections of phosphate-buffered
buffered saline (PBS) (controls) or mithramycin A (mithramycin)
(
(0.25 mg/kg). Total protein lysates were extracted from the tumors, from the livers of
mice that received treatment with PBS or mithramycin 24 hours after injections, and from
the livers of untreated mice (control). (A) Western blot analysis was used to determine
the expression of Sp1, vascular endothelial growth factor (V
(VEGF),
EGF), epidermal growth
factor receptor (EGFR), and platelet
platelet-derived
derived growth factor (PDGF) in tumors that were
growing in mice that had received 2 injections of PBS or mithramycin either
intraperitoneally (mithramycin
mithramycin/i.p.) or mithramycin/s.c.) GAPDH indicates
es glyceraldehyde
3-phosphate
phosphate dehydrogenase. (B) The levels of Sp1 expression were determined in both
tumors and normal tissues by using Western blot analysis.
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PART 2. ROLE OF SP1 IN CURRENT ANTI-ANGIOGENIC THERAPY IN
PANCREATIC CANCER
Bevacizumab

and

mithramycin

combination

produced

synergistic

antitumor effects in human pancreatic cancer mouse models

Several researches have reported that Sp1 is the key for VEGF expression.
VEGF plays an important role in regulating pancreatic cancer angiogenesis.
However, whether Sp1 signaling was altered and what role that Sp1 has in antiVEGF anti-angiogenic therapy is unknown.

To address these questions, the anti-tumor effect of anti-VEGF monoclonal
antibody Bevacizumab was tested. Specifically, a dose-response experiment was
first performed. BxPC3 cells were injected into subcutis of nude mice. When the
resulting tumors reached 4 mm in greatest dimension, Bevacizumab (25, 50, and
100 µg; Fig. 14) was given to the animals via i.p. injection twice a week. PBS was
injected to a group of animals as controls. It was found that treatment with
Bevacizumab produced dose-dependent antitumor activity. The mice that
received Bevacizumab did not have significant body weight lose (Fig. 14). The
experimental result suggested that Bevacizumab did not have any systemic side
effects at the doses given.
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Figure 14 Dose-dependent
dependent antitumor effects of Bevacizumab in xenograft models
of human pancreatic cancer. BxPC3 cells were injected into the subcutis of nude mice
(n = 5). When tumors reached around 4 mm in diameter, the animals received different
doses of Bevacizumab [25 ((B-25), 50 (B-50), and 100 (B-100)) µg] via i.p. injection twice
a week. Tumors were meas
measured
ured once every week, and at each measurement, the mean
± SD tumor volume in the five mice in each group was calculated. The
he control mice and
mice that received were weighed at the time of experiment termination. Columns, mean
weights; bars, SD. * P < 0.01 in a comparison between the treated and respective
control groups.
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Next, I sought to determine the treatment effect of the combination of the
Bevacizumab and mithramycin at the dose that has minor anti-tumor effect.
Experiments were performed using both BxPC3 and PANC-1 tumor cell models.
Specifically, PBS, Bevacizumab (25 µg), mithramycin (0.10 mg/kg), or B + M
were given to a group of nude mice. Consistent with last experimental result,
administration of Bevacizumab or mithramycin alone produced minor antitumor
activity. In contrast, administration of B + M produced synergistic antitumor
activity without any observed systemic side effects (Fig. 15). Also, the mice body
weights that received B + M is similar to the control mice that received PBS.
Therefore, the use of B + M produced higher antitumor activity than the use of
Bevacizumab or mithramycin alone did and no increased toxicity observed.
These experimental results suggested that B + M treatment has a significant
therapeutic benefit in pancreatic cancer mouse model.

64

Figure 15 Synergistic antitumor effects of treatment with Bevacizumab and
mithramycin in xenograft models of human pancreatic cancer. Both (A) BxPC3 and
(B) PANC-1 cells were injected into the subcutis of groups of mice (n = 5). Specifically,
animals received injections of PBS (controls), Bevacizumab (25 µg), mithramycin A (0.10
mg/kg), or B + M. Tumors were measured once every week, and at each measurement,
the mean ± SD tumor volume in the five mice in each group was calculated. A and B, * P
< 0.01 in a comparison between the treated and respective control groups. C,
representative tumor sizes in each group of BxPC3 model mice.
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Bevacizumab and mithramycin produced prolonged survival in orthotopic
xenograft model of human pancreatic cancer
PANC-1 cells were injected into the pancreas of nude mice and then treatments
were given to them as described in Figure 15. Animal survival was monitored
daily. The experiment was terminated at 160 days after tumor-cell injection. It
was found that Bevacizumab or mithramycin alone treatment produced a slightly
increased survival duration comparing with PBS group. However, the B + M
combination treatment produced longer survival duration when comparing with
the other three groups of mice and the difference was statistically significant (Fig.
16A). In addition to this, the decreased incidence of tumor growth in the pancreas
and of metastasis in the liver and/or other organs was found in the B + M
combination treatment group (Fig. 16B). The decrease is statistically significant.
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Figure 16 Prolonged survivals of mice that received treatment with Bevacizumab
and mithramycin in xenograft models of human pancreatic cancer. PANC-1 cells
were injected into the pancreas of nude mice (17–20 mice per group). The mice received
treatment as described in Fig. 15. The entire experiment was terminated 120 days after
tumor-cell injection. A, animal survival was monitored daily until the termination of the
experiment. Cum, cumulative. B, tumor growth in the pancreas and metastasis in the
liver and/or other organs were evaluated and expressed as the incidence (%). * P < 0.01
in a comparison between the treated and respective control groups.

67

Bevacizumab treatment up-regulates Sp1 and VEGF expression and its
reversal by treatment with mithramycin
In this experiment, genes expression analysis was used to determine the
mechanism of the synergistic effect of B + M combination treatment.
Specifically, PANC-1 tumor tissues were harvested from mice that received
treatment with PBS, Bevacizumab, mithramycin, or B + M. The tissue specimen
were then stained using specific antibodies against Sp1, VEGF and CD31
respectively. Representative pictures from each group were shown in Figure 17.
As it shows, Bevacizumab treatment increases Sp1 and its downstream molecule
VEGF expression. However, treatment with mithramycin suppressed Sp1 and
VEGF expression, which was consistent with reduced MVD (Fig. 17 and 18 A),
whereas treatment with Bevacizumab at the low dose alone did not significantly
reduce MVD, which was consistent with increased Sp1 expression.
Next western blot analysis was performed. Tumor tissue specimens were
collected from

mice

that

received

treatment

with

PBS,

Bevacizumab,

mithramycin, or B + M. Total protein lysates were extracted and run western blot
analysis As shown in Fig. 18B and C. Consistent with the immunohistochemistry
staining results, the expression of Sp1 and its downstream angiogenic factor
VEGF were up-regulated by Bevacizumab treatment.
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Figure 17 Gene expression analyses of tumor from mice that received treatment
with Bevacizumab and mithramycin in xenograft models of human pancreatic
cancer. Sp1, VEGF expression were determined in PANC-1 tumor tissues collected
from mice that received treatments in the experiment described in Figure 15 using
immunohistochemistry. MVD status was assessed by using CD31 staining.
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Figure 18 Analysis of MVD and gene expression of tumor from mice that received
treatment with Bevacizumab and mithramycin in xenograft models of human
pancreatic cancer. The tumor tissues described in Fig. 15 were collected and
processed as described in Materials and Methods. A, MVD was quantitated according to
CD31 staining. B, total protein lysates were harvested from tumor tissues and the level
of protein expression in them was determined using Western blot analysis. Equal
protein-sample loading was monitored by probing the same membrane filter with an
anti–β-actin antibody. NS, nonspecific band. C, the levels of Sp1 and VEGF expression
were quantitated and expressed as fold change. * P < 0.01 in a comparison between the
treated and respective control groups.
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Figure 19 Analysis of Sp1 and VEGF expression in tumor tissues. The tumor
tissues described in Fig. 14 were collected and western blot analysis was done using
specific antibodies against Sp1, VEGF, and β-actin.
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These data indicated that the Bevacizumab neutralizes circulating VEGF and
Sp1 expression may be up-regulated through the positive feedback loop, which
may lead to increased VEGF expression in cell. However, because of the initially
decreased VEGF neutralized by Bevacizumab, the MVD levels may be
decreased for some degree. However, Sp1 up-regulation may also activate the
other downstream angiogenic protein besides VEGF. The over-expression of
these angiogenic proteins might trigger the tumor’s resistance to Bevacizumab
treatment.

As it was shown, low dose of Bevacizumab (25 µg) treatment that activates Sp1
expression does not have significant antitumor activity. Expression level of Sp1 in
tumors harvested from mice that received high dose of Bevacizumab (100 µg)
treatment, which had a significant antitumor activity, was determined. The
western blot result was shown in Fig. 19. Sp1 protein level was found to be
decreased by the 100 µg of Bevacizumab treatment. However, Sp1 expression
up-regulation by the 25 µg of Bevacizumab treatment was also observed. It was
also found that the alteration of VEGF expression level was consistent with that
of the Sp1 expression level. These data indicated that the ineffective low dose of
Bevacizumab treatment could up-regulate Sp1 expression and might contributed
to Bevacizumab resistance.
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Bevacizumab and mithramycin treatment effect on the growth and gene
expression in human pancreatic cancer cells

Since Bevacizumab treatment could up-regulate Sp1 and its downstream
angiogenic molecules in vivo, I then want to determine how that affect gene
expression in pancreatic cancer cells in vitro. PANC-1 and BxPC3 cells were
incubated in 100µg/ml of Bevacizumab in culture medium. Cells were harvested
in 6, 12, 24 and 48 hours and cell number were counted in day 1 to 5. As it was
shown in Figure 20, Bevacizumab treatment did not affect BxPC3 cells growth
(Fig. 20A) or PANC-1 cells growth (Fig. 20B) in vitro. The western blot was
shown in Fig. 20C. Neutralization of VEGF by Bevacizumab treatment did not
affect the expression of Sp1 and its downstream molecules VEGF and EGFR. As
it was reported previously that Bevacizumab primarily neutralizes the circulating
VEGF to block its autocrine effect on tumor angiogenesis [124, 147-149, 185].
This was confirmed by the current experimental result.

However, mithramycin treatment inhibits PANC-1 cells (Fig. 21A) growth in vitro
in dose-dependent manner. The IC50s of 24 and 48 hours of mithramycin
treatment were >1.5 µmol/L and 0.15 µmol/L respectively. But 0.05 and 0.10
µmol/L of mithramycin treatment inhibited the expression of Sp1 and its
downstream molecules EGFR and VEGF in PANC-1 cells (Fig. 21B). These data
indicated that mithramycin treatment inhibited tumor cells growth and down-

73

regulated

Sp1

and

its

downstream

molecules’

expression.

Whereas

Bevacizumab did not has the effect.
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Figure 20 Effects of treatment with Bevacizumab on the growth of and gene
expression in human pancreatic cancer cells in vitro. BxPC3 (A) and PANC-1 cells
(B) were incubated for 1 to 5 d in medium alone or a medium containing 100 µg/ml
Bevacizumab. The viable cells were counted every 24 h. C; PANC-1 cells were
incubated for 6 to 48 h in medium alone or a medium containing 100 µg/ml
Bevacizumab. Total protein lysates were harvested from the cell cultures, and the level
of Sp1, EGFR, and VEGF protein expression was determined using Western blot
analysis. Equal protein-sample loading was monitored by probing the same membrane
filter with an anti-GAPDH antibody.
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Figure 21 Effects of treatment with mithramycin on the growth of and gene
expression in human pancreatic cancer cells in vitro. A and B, PANC-1 cells were
treated with mithramycin at concentrations ranging from 0.1 to 1.2 µmol/L for 24 and 48
h. A, cytotoxicity was assessed using the 3-(4,5-dimethylthiazol-2-thiazolyl)-2,5diphenyltetrazolium bromide assay. B, the level of gene expression was determined
using Western blot analysis. NS, nonspecific.
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Effects of Bevacizumab and mithramycin treatment on Sp1 recruitment into
the Sp1 promoter in vitro and in vivo in human pancreatic cancer cells
As it was shown previously, mithramycin treatment down-regulated Sp1 protein
expression and B + M combination treatment produced significant anti-tumor
effect. I then sought to determine the molecular mechanism. Luciferase assay
was performed to determine Sp1 promoter activity. Briefly, Sp1 promoter reporter
constructs were transfected into PANC-1 cells. The cells were then incubated in
100µg/ml Bevacizumab or 0.1µmol/L mithramycin in culture medium. Mithramycin
treatment suppressed

Sp1

promoter

activity

significantly

in

vitro,

but

Bevacizumab treatment did not. However, Sp1 promoter activity suppression
produced by mithramycin treatment was eliminated by further deletion of Sp1binding sites in its promoter (Fig. 22 A and B).
Next ChIP assay was used to further determine the mechanism. Consistently,
mithramycin treatment significantly reduced Sp1 protein recruiting onto its own
promoter as shown in Figure 23 A, whereas Bevacizumab treatment (100µg/ml)
did not produce this effect. Then tumors tissues harvested in the experiment
described in Figure 15 were used to perform ChIP assay. Both mithramycin
treatment and B + M treatment suppressed Sp1 protein recruitment to its own
promoter (Fig. 23B). These data suggested that mithramycin treatment
interposes Sp1 recruitment on its promoter and blocks Sp1 transcription to downregulate Sp1 and its downstream target molecules, such as VEGF. This might
disrupt the positive feedback produced by Bevacizumab.
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Figure 22 Effects of Bevacizumab and mithramycin treatment on Sp1 promoter
activity in vitro. A, schematic structures of the minimal Sp1 promoters. The nucleotide
positions and sequences of Sp1-binding sites and PCR forward and reverse primers
flanking those sites for ChIP assay are shown. B, Sp1 promoter reporter constructs were
transfected into PANC-1 cells in triplicate and incubated for 12 h. The cells were then
incubated for another 24 h in medium alone or a medium containing 100 µg/ml
Bevacizumab or 0.1 µmol/L mithramycin. Total protein lysates were harvested from the
cell cultures for measurement of Sp1 promoter activity using a luciferase assay kit. The
relative Sp1 promoter activities were assessed, and the activity in treated groups was
expressed as the fold change of that in their respective control groups.
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Figure 23 Effects of treatment with Bevacizumab and mithramycin on Sp1
recruitment into the Sp1 promoter in human pancreatic cancer cells in vitro and in
vivo. A, chromatin was extracted from PANC-1 cells that were incubated in vitro for 2 d
in medium alone or a medium containing 100 µg/
µg/ml Bevacizumab or 0.1
0 µmol/L
mithramycin. B, chromatin was extracted from tumors formed by PANC-1
1 cells in nude
mice that received treatment as described in Fig. 15.. The ChIP assay was done using a
specific anti-Sp1
Sp1 antibody and oligonucleotides flanking the Sp1 promoter regions
containing Sp1-binding
binding sites. Lane 1, input chromatin DNA; lane 2, chromatin DNA with
control IgG; lane 3, chromatin DNA with anti
anti-Sp1 antibody. Ctr, control.
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In this part, it was found that treatment with ineffective low dose of Bevacizumab
up-regulated Sp1 expression. This positive feedback is then positive regulate the
expression of various angiogenic factors, including VEGF. Mithramycin treatment
inhibited Sp1 expression and repressed VEGF expression and tumor
angiogenesis. Low doses of B + M combination treatment produced a synergistic
anti-angiogenic effect (super additive at least). This effect was correlated with
Sp1suppression activity and Sp1 downstream target molecules down-regulation.
These experimental findings suggested that Bevacizumab block VEGF signaling
in vivo may triggers the positive feedback to up-regulate p1 expression. This
feedback might leads to the up-regulation of multiple angiogenic factors including
VEGF in turns. In this way, Bevacizumab treatment neutralizes VEGF and may
lead to compensatory up-regulation pathways, such as transcription factor Sp1,
which may lead to drug resistance as consequence. However, mithramycin
treatment interfere Sp1 recruitment onto its promoter and inhibit Sp1 expression
to block this feedback mechanism. For the first time, it was shown that Sp1 was
regulated by itself and this auto-regulation can be interrupted by mithramycin.
These findings provide a novel paradigm of synergism between anti-angiogenic
and chemotherapeutic reagent. This might help physician in designing regimens
that can improve anti-angiogenic activity and reverse resistance in antiangiogenic therapy.
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DISSCUSSION
In this chapter, it was demonstrated that mithramycin, a Sp1 inhibitor, has
significant anti-pancreatic cancer capability. The experimental results indicated
that mithramycin has strong anti-angiogenic capability with no systemic side
effects observed at a given dose. Low dose of mithramycin treatment did not
inhibit tumor angiogenesis significantly when comparing with high dose treatment.
But low dose of mithramycin treatment did reduce Sp1 and its downstream
angiogenic molecules’ expression the in tumors. The impact of mithramycin
treatment on the expression of Sp1 in xenograft tumors and non-tumor tissues
were evaluated. This is to determine the Sp1 inhibition ability of mithramycin on
normal tissue at the given dose, which was then used to modify the responses
and optimize its treatment strategy. Whether mithramycin preferentially affects
neo-angiogenesis and tumor-associated stem cells is unknown and could be
further investigated. Besides the anti-angiogenic effect, the mithramycin
treatment may produce antitumor activity through a mechanism of induction of
tumor cell apoptosis in vivo. These indicated that mithramycin may affect tumor
cell survival by more than only one anti-angiogenic mechanism. As it was
reported by other labs that mithramycin could sensitize of tumor cells to
apoptosis induction through tumor necrosis factor-alpha-related apoptosisinducing ligand, Fas ligand and tumor necrosis factor [177, 179, 180].
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Lots of experimental results demonstrated that angiogenesis had important roles
in maintained growth and metastasis of pancreatic cancer. Studies reported by
different groups showed that pancreatic xenograft tumors in mouse model were
suppressed by anti-angiogenic treatment [124, 126, 150]. Several strategies that
target VEGF signaling and function have been designed and tested. Pancreatic
cancer angiogenesis, growth, and metastasis were inhibited and survival was
improved in nude mouse models. Anti-VEGF antibodies, VEGF antisense oligonucleotides, VEGF-directed ribozymes and VEGF fused to a diphtheria toxin
were all demonstrated to be effective. Also VEGF receptor interference was
developed, such as dominant-negative flk-1, and the small molecules tyrosine
kinase inhibitors targeting VEGF receptors [144, 146, 186, 187]. Even the specific
cyclooxygenase-2 inhibitor celecoxib was shown to suppress pancreatic cancer
growth and metastasis through inhibiting VEGF expression. The other antioxidant isoflavone genistein was also reported to suppress angiogenesis through
down-regulating VEGF [130, 188, 189]. It was also reported that the expression
of VEGF correlates with MVD status and disease progression in different types of
tumors [58, 84]. All the results from different clinical researches and experimental
designs using different approaches indicated that angiogenesis is very
importance in tumor biology. VEGF played a crucial role in tumor angiogenesis.

In xenograft mouse models, it has been shown that targeting VEGF produced
inhibited tumor growth, but the VEGF targeting reagent was reported to have
limited response when used as mono-agent regimen in clinic studies [148, 190].
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Tumor cells need to be destroyed instead of to be kept static by therapeutic
drugs to cure cancer. It has been shown that anti-angiogenic approaches
produced more effective results when they were used together with
chemotherapy and/or radiation therapy. In combination with other strategies
VEGF targeting were reported to be more effective for neuroendocrine tumor,
renal cell carcinoma, and some sarcomas [191-196]. Also, gemcitabine was
reported to facilitate anti-angiogenic therapies when used together with antiVEGF, anti–VEGF receptor and anti-EGFR antibodies [185, 197-199]. Antiangiogenic therapies that target single molecule produced limited therapeutic
effect suggested the importance of targeting several angiogenic signals and
effectors factors at the same time [58]. Targeting these individual molecules
might also potentially result in resistance to the targeting drug through feedback
mechanisms.

Recently Bevacizumab was used in combination with gemcitabine, capecitabine
for advanced local-regional pancreatic cancer in randomized phase II and III
clinical trials. It was also used as combination with rapamycin, everolimus,
erlotinib or oxaliplatin in treatments of other type of cancer and produced
promising results in clinical trials [200-202]. Mechanisms have been proposed for
the synergy between anti-angiogenic therapy and chemotherapy. It was proposed
that VEGF targeted therapeutics may stabilize mature blood vascular since
VEGF was demonstrated to be a vascular permeability factor. Thus interstitial
fluid pressure was decreased, which may in turn enhance chemotherapy reagent
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delivery [203]. There is research even pointed out that pancreatic cancer
treatment needs to enhance vasculature to achieve better chemotherapeutic
results [204]. On the other hand, it was also proposed that Bevacizumab
treatment may reverse apoptotic resistance mediated by neuropilin receptors
[124, 205].

Several other angiogenic growth factors, such as FGFs, EGF, HGF, transforming
growth factor-α and platelet-derived growth factor were also reported to be overexpressed in pancreatic cancer cells [58, 84]. It has been reported that the
expression of these and many other factors correlate with increased vasculature
and poor prognosis in pancreatic cancer patients [58, 84, 85]. Therefore, other
factors are involved in the pancreatic cancer growth and metastasis process as
well as VEGF. In autocrine and paracrine fashion, these factors produce
angiogenic activity to promote pancreatic cancer cell growth and angiogenesis
and enhance pancreatic tumor metastasis eventually [84, 85]. It was reported that
angiogenesis and growth of pancreatic cancer could be interrupted by interfering
the expression or function of the angiogenic factors discussed in mouse models.
Such as dominant-negative IGF-IR (IGF/IGF-1R interferer) or NK4 (a competitive
antagonist of HGF) treatment produced anti-angiogenic activity [58, 84]. It would
be predicted that targeting these angiogenic factors at the same time would
produce promising therapeutic effect. However, it has been a clinical challenge
for multiple targeting at the same time.
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Previous experimental results have indicated that a potential underlying
mechanism for over-expression of various angiogenic factors exited. With this
mechanism, angiogenesis was collectively regulated with the over-expression of
the angiogenic factors as the directed result [58, 88]. Angiogenic signals carried
by these angiogenic factors transduced through intra-cellular signal net work and
converged to transcription factors. In pancreatic cancer one of the transcription
factor Sp1 is reported to be constitutively over-expressed in vitro. The constitutive
and inducible VEGF expression depends on the Sp1constitutive activity [58, 61,
88, 108, 134]. It was also reported that over-expression of Sp1 is correlated with
MVD in human gastric cancer specimen assessed by immunohistochemistry
staining [58, 88]. In the present study mithramycin treatment was shown to
interpose Sp1 recruitment onto its own promoter, which blocked Sp1 transcription
and decreased Sp1 protein. This is correlated with the suppressed tumor
angiogenesis and growth in vivo. All of these evidences indicate that Sp1 plays
important roles in the regulation of angiogenesis and Sp1/VEGF signaling
pathway is important in pancreatic cancer.

Mithramycin treatment at the ineffective low dose did not produce significant
antitumor activity in the present study. But in tumors the VEGF protein level was
reduced when comparing with control group. This result indicated that
mithramycin treatment at the given dose inhibits Sp1 and VEGF expression, but
there are small amount of extracellular matrix–associated VEGF in the tumor bed
or the circulating VEGF remaining. These two parts of VEGF residues may
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initiate angiogenesis. The angiogenic phenotype may also be maintained by the
small amount of VEGF leftover. It is critical, if that is the case, to remove the
remaining VEGF to diminish the angiogenic signals. This might be the reason that
why the given low dose of mithramycin treatment cannot produce significant
antitumor activity. It was also observed that many Sp1 downstream angiogenic
molecules, including VEGF, were up-regulated by low dose of Bevacizumab
treatment. This might be the reason why treatment with Bevacizumab as single
drug was not sufficient to produce sustained anti-angiogenesis. However, the
combination of Bevacizumab and mithramycin can neutralize soluble and
membrane bounded VEGF, block the feedback on Sp1 and its downstream
angiogenic molecules and produce synergistic anti-angiogenic effect in
pancreatic xenograft mouse models. All of these experimental results suggesting
that Sp1 and Sp1/VEGF signaling are very important in pancreatic cancer
angiogenesis.

Collectively, the present experimental results suggest that VEGF targeting
treatment, such as Bevacizumab, may trigger the drug resistance in pancreatic
cancer. The positive feedback through activated Sp1 expression and Sp1
downstream angiogenic molecules’ activation as the consequence might be one
of the underlying mechanisms. The combination treatment of mithramycin and
Bevacizumab can block Sp1 transcriptional regulation and neutralize VEGF,
which is a novel strategy of targeting angiogenesis. The proposed molecular drug
resistance formation model might be extended to other type of cancer
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therapeutics besides pancreatic cancer and other type of therapy besides antiangiogenesis. The rationale represented by the combination use of Bevacizumab
and mithramycin would push the pancreatic cancer anti-angiogenic therapy step
forward.
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CHAPTER III
Synergistic Antitumor Regulation of Mithramycin and
Tolfenamic acid of Pancreatic Cancer in Mouse Models
INTRODUCTION
ANTI-ANGIOGENIC THERAPY APPROACHES AND REATIONAL

As it has been discussed previously, angiogenesis is an important process for
tumor cell survival and metastasize to distant organs. It is dynamically regulated
by lots of angiogenic factors and angiogenic inhibitors [66, 181].

Under the

hypoxia condition in tumor micro-environment, angiogenic factors are overexpressed and predominate over angiogenic inhibitors. These angiogenic factors
whose over-expression leads to the imbalance are the targets of current antiangiogenic targeted therapies [66, 82, 86, 87, 206]. Among the growing list of
angiogenic factors, VEGF is considered as one of the very important ones for
most of the tumor types.

Among current anti-VEGF target therapies, Bevacizumab is considered to be one
of the most successful ones. Bevacizumab is the first FDA approved antiangiogenic medicine. It is a humanized murine monoclonal Antibody [207]. Its
murine origin is A4.6.1. It recognizes VEGF121, 165 and 189 [208]. The in vivo
embryonic chicken angiogenesis and vascular permeability assay showed it can
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neutralize VEGF. In preclinical study, xenograft tumor growth was inhibited by
Bevacizumab treatment [148, 183, 209-211]. Bevacizumab is now used in
different phases for different types of cancer. It is now the 1st line medicine of
colon cancer treatment.

It is known that VEGF transcriptional control is also being used. The most
important one is HIF-1α targeted therapy from each level. HIF-1α is monomer
that can form heterodimeric transcription factor HIF. HIF-1β (or Arnt) is the other
component. HIF can bind to hypoxia-response element (HRE, which contains the
consensus core sequence 5’-R(A/G)CGTG-3’ ) and activates the transcription of
VEGF and VEGFR1 [212]. HIF-1α is over-expressed in most types of solid
tumors. Its expression might be activated by intra-tumoral hypoxia and genetic
alterations, including oncogenic gain-of-function mutations and tumor-suppressor
loss-of-function mutations, such as VHL (Von Hippel-Lindau) and PTEN. Under
hypoxic condition, VEGF transcription is up-regulated by HIF heterodimer binding
on the HRE in its promoter region. There is also an internal ribosomal entry site
allowing preserved translation when facing normal cellular hypoxic shutdown.
VEGF biological function is also influenced by hypoxia-inducible expression and
post-transcriptional regulation of VEGF receptors. Mouse genetics study shows
inactivation of HIF-1α resulting in abnormal vascular development and embryonic
lethality. The HIF-1α-/- mice have angiogenic defects in both the yolk sac and the
development of embryonic tissue [213].
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A variety of genetic and pharmacologic approaches have been used to target
HIF-1α. As a transcription factor, its DNA binding affinity can be targeted; its
protein stability can also be targeted since it has a natural stable/degraded
regulation mechanism; its mRNA stability can also be targeted using siRNA(small
interfering RNA) technology; its protein level may be targeted by regulating the
translation process; the important PI3K/Akt signaling pathway is another aspect
of HIF-1α targeting to affect its transcription; the nuclear translocation of HIF-1α
and the dimerization process may be desirable targets for the inhibition of HIF-1
activity [214].

As a receptor of VEGF signaling pathway, the most important angiogenesis
signaling pathway, VEGFRs are certainly the hot targets of anti-angiogenic
therapy. Although with questionable specificity, small molecule tyrosine kinase
inhibitor (TKI) is always the hot spot of VEGFR targeting research. VEGFR can
also be targeted by chimeric receptor and VEGF trap (soluble chimeric VEGFR).
They can all inhibit tumor growth in vivo. Antisense oligonuleotides is also used
to target VEGFR. Besides these, small molecule VEGFR-2 kinase and
phosphorylation inhibitors are used. Neutralizing Antibodies directed against
VEGFR such as DC101, IMC-1C11and CDP791 were also developed.

USE OF MITHRAMYCIN IN SP1 MANIPULATION

Mithramycin is an antibiotic that has antitumor activity as shown in the last
chapter. It is produced by the bacteria of the genus Streptomyces sp and can
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bind to Sp1 site in DNA sequence [164, 165]. Mithramycin can compete with
transcription factor binding to promoters and block transcription activation. After
binding on DNA, it forms a stoichiometry drug-mental complex through the
chelation with divalent ion. This interaction is non-covalent and is reversible [168,
175, 215]. It is believed that mithramycin selectively competing with Sp1 to
regulate the transcription of genes that have Sp1 site(s) in their promoter region
[175, 176, 216]. As it has been shown in last chapter, mithramycin treatment
down-regulates Sp1 protein through blocking Sp1 transcriptional auto-regulation
and decreases Sp1 downstream angiogenic molecules as a consequence. The
major mechanism of mithramycin antitumor effect is believed to inhibit Sp1
activity [217]. While this manipulation to Sp1 protein is the result of Sp1mRNA
transcription blockage instead of working on the protein molecules directly.

TOLFENAMIC ACID (TA) HAS ANTI-TUMOR ACTIVITY

Tolfenamic acid is a prostaglandin as well as leukotriene synthesis inhibitor
through blocking cyclooxygenase catalytic activity. It is a well-documented and
effective non-steroidal anti-inflammatory drug for treatment of migraine symptom.
It can relieve endometriosis symptoms in patients with pelvic endometriosis
through inhibiting prostaglandin synthetase and antagonizing prostaglandins at
the target level [218]. It is also used to diminish the local reactions after telecobalt
therapy [219]. TA has a long history to be used in treating acute migraine attack
either alone or with caffeine, metoclopramide and pyridoxine as adjuncts [22091

222]. When TA was used together with sumatriptan, migraine recurrence
decreased dramatically [223]. Recently, TA is reported to be an urokinase
plasminogen

activator

inhibitors

in

a

computational

study by docking

nutraceuticals to the 3D structure of urokinase [224]. It was also reported to
activate Sp1, Sp3, and Sp4 protein degradation in pancreatic cancer cells and
this was accompanied by decreased VEGF and VEGF receptor 1 in both mRNA
and protein level [225, 226].

In this chapter, the synergistic anti-tumor effect of mithramycin and TA
combination and the corresponding anti-angiogenic, cell growth inhibition
mechanism were investigated.
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MATERIALS AND METHODS
Chemicals and Reagents Information

Mithramycin (1 mg/vial crystal powder) and TA were purchased from Sigma
Chemical Co. (St. Louis, MO). Mithramycin was dissolved in sterile water
diluted for actual use. TA was mixed with corn oil (Sigma Chemical Co., St.
Louis,

MO) to

corresponding concentration.

For animal experiments,

mithramycin was administered by intraperitoneal injection twice a week or as
indicated otherwise. TA was administered through oral gavage.

Cell Lines and Culture Conditions Information

The resources of human pancreatic adenocarcinoma cell lines PanC-1, FG and
BxPC3 are the same as previous chapters. The cell lines were maintained in
plastic

flasks

as

adherent

monolayers in

minimal

essential

medium

supplemented with 10% fetal bovine serum, sodium pyruvate, nonessential
amino acids, L-glutamine, and a vitamin solution (Flow Laboratories, Rockville,
MD).

Animals Information

Female athymic BALB/c nude mice were purchased from The Jackson
Laboratory (Bar Harbor, ME). The mice were housed in laminar flow cabinets
under specific pathogen-free conditions and used when they were 8 weeks old.
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The animals were maintained in facilities approved by the Association for
Assessment and Accreditation of Laboratory Animal Care in accordance with
current regulations and standards of the U.S. Department of Agriculture, U.S.
Department of Health and Human Services, and National Institutes of Health in
M D Anderson Cancer Center animal facility.

Western Blot Analysis Protocol

Whole-cell lysates were prepared from human pancreatic cancer cell lines or
tissues [61]. Standard Western blotting was performed using polyclonal rabbit
antibodies against human and mouse Sp1, VEGF (Santa Cruz Biotechnology,
Santa Cruz, CA) and the anti-rabbit IgG antibody, a horseradish peroxidaselinked F(ab')2 fragment obtained from a donkey (Amersham, Arlington Heights,
IL). Equal protein-sample loading was monitored by probing the same
membrane

filter

with

antibodies

against

glyceraldehyde-3-phosphate

dehydrogenase [227]. The probe proteins were detected using the Amersham
enhanced chemiluminescence system according to the manufacturer’s
instructions.

Matrigel Plug Assay
Matrigel (200µl) containing 2 × 106 cells were injected subcutaneously into nude
mice (2 injection sites per mouse). The Matrigel plugs were recovered from the
mice 10 days after injection and carefully stripped of host tissues. After
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photomicrography, the Matrigel plugs were weighed and homogenized in 1 ml of
distilled water and then centrifuged at 10,000 revolutions per minute for 5
minutes. The supernatants were collected for hemoglobin measurement using
Drabkin solution (Sigma Chemical Company, St. Louis, MO) and a Microplate
Manager enzyme-linked immunosorbent assay reader at 540 nm according to
the manufacturer’s instructions. The relative hemoglobin concentrations were
calculated and further normalized according to the weights of the plugs.

Immunohistochemical Analysis and Quantification of Tumor MVD

For CD31 staining, frozen tissue sections (5µm thick) were fixed in acetone.
Endogenous peroxidase in the specimens was blocked using 3% hydrogen
peroxide in PBS for 12 minutes. The specimens were incubated for 20 minutes
at room temperature in a protein-blocking solution consisting of PBS (pH 7.5)
containing 5% normal horse serum and 1% normal goat serum and then
incubated overnight at 4°C in a 1:100 dilution of monoclonal goat anti-CD31
(PECAM1-M20), polyclonal rabbit anti-Sp1, polyclonal rabbit anti-VEGF or
polyclonal rabbit anti-PCNA antibodies (Santa Cruz Biotechnology) [229]. The
specimens were then rinsed and incubated with peroxidase-conjugated antigoat or anti-rabbit IgG for 1 hour at room temperature. Next, the slides were
rinsed with PBS and incubated with diaminobenzidine (Research Genetics,
Huntsville, AL) for 5 minutes. Frozen sections of the specimens were then
washed three times with distilled water, counterstained with Mayer’s
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hematoxylin (Biogenex Laboratories, San Ramon, CA), and washed once each
with distilled water and PBS. The slides were mounted with Universal Mount
(Research Genetics) and examined under a bright-field microscope. A positive
reaction was indicated by a reddish-brown precipitate in the cytoplasm (CD31)
or nuclei (Sp1). For quantification of tumor MVD, vessels on each section were
counted in five high-power fields (magnification, x200 [x20 objective and x10
ocular]) as described previously [230, 231].

Chromatin Immunoprecipitation Protocol

Chromatin was prepared from cells and tumors as described previously [59].
Chromatin Immunoprecipitation (ChIP) assay was done using the Chromatin
Immunoprecipitation Assay Kit (Upstate Cell Signaling Solutions) according to
the manufacturer’s instructions. Briefly, DNA cross-binding proteins were crosslinked with DNA and lysed in SDS lysis buffer. The lysate was sonicated to
shear DNA to 200 to 1000 bp. After pre-clearing with a salmon sperm
DNA/protein A agarose–50% slurry for 30 min at 4°C, chromatin samples were
immunoprecipitated overnight with no antibody or an anti-Sp1 antibody (PEP2).
The region between -224 and -53 bp of the Sp1 promoter was amplified using
the following primers: sense, 5'-caggcacgcaacttagtc-3', and antisense, 5'gtaaggaggagggagcag-3'. The region between -272 and +18 bp of the VEGF
promoter

was

amplified

using

the

following

primers:

sense,

5'-

ccgcgggcgcgtgtctctgg-3', and antisense, 5'-tgccccaagcctccgcgatcctc-3'. PCR
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products were separated on a 1.5% agarose gel, stained with ethidium bromide,
and visualized under UV light.

Statistical Analysis

Each experiment was done independently at least twice with similar results;
one representative experiment is presented. The significance of the in vitro data
was determined using Student’s t test (two-tailed), whereas the significance of
the in vivo data was determined using the two-tailed Mann-Whitney U test. For
the in vivo experiments, the overall survival duration was calculated using the
Kaplan-Meier method. The log-rank test was used to compare the survival
duration between groups. P ≤ 0.05 was deemed significant.
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RESULTS
Effects of treatment with mithramycin and/or tolfenamic acid on the gene
expression in human pancreatic cancer cells

To determine the impacts of mithramycin and TA treatment on gene expression
in pancreatic cancer cells, PANC-1 and BxPC3 cells were incubated in a medium
alone or a medium containing mithramycin (0.01, 0.05 and 0.1 µmol/L) and/or TA
(5, 10, 20 µmol/L). Western blot results showed that Sp1 protein level was downregulated by both mithramycin and TA treatment as single reagent in a dosedependent pattern after 24 hours of treatment (Fig. 24A and 24B) in vitro.

As shown in Fig. 25, low dose of mithramycin and TA combination treatment can
significantly down-regulate Sp1 protein level. These data suggested that high
dose of mithramycin and TA treatment can decrease Sp1 protein level
significantly at around 24 hours and low dose of mithramycin and TA combination
produced synergistic down-regulation effect on Sp1 protein at around 12 hours.
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Figure 24 Tolfenamic acid, mithramycin treatments down-regulate Sp1 in vitro
PANC-1 cells were incubated in medium alone or a medium containing mithramycin or
TA. Total protein lysates were harvested from the cell cultures, and the level of Sp1 and
VEGF protein expression was determined using Western blot analysis. Equal proteinsample loading was monitored by probing the same membrane filter with an antiGAPDH antibody. A1, mithramycin (0.01, 0.05 and 0.1 µmol/L) were used to treat
PANC-1 cells and samples were harvested at 24hours. A2, the quantitative results of
Sp1 and VEGF in A1 normalized with GAPDH; Blank treatment was set as 100%. B1,
TA (5, 10, 20 µmol/L) was used to treat PANC-1 cells and sample were harvested at 24
hours. B2, the quantitative results of Sp1 and VEGF in B1 normalized with GAPDH;
Blank treatment was set as 100%.
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Figure 25 Tolfenamic acid/mithramycin treatments down-regulate Sp1 in vitro
PANC-1 cells were incubated in medium alone or a medium containing mithramycin
and/or TA. Total protein lysates were harvested from the cell cultures, and the level of
Sp1 and VEGF protein expression was determined using Western blot analysis. Equal
protein-sample loading was monitored by probing the same membrane filter with an antiGAPDH antibody. A, Mithramycin (0.05 µmol/L) and TA (5 µmol/L) was used to treat
PANC-1 cells and samples were harvested at 12 hours. B, the quantitative results of Sp1
and VEGF in A normalized with GAPDH. Blank treatment was set as 100%.
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Tolfenamic acid and mithramycin treatments down-regulate Sp1 protein
through different mechanism

As it was shown in last chapter, mithramycin down-regulates Sp1 expression
through interfere its recruitment on its own promoter to block Sp1 mRNA
transcription. To determine how TA treatment regulates Sp1 protein expression
in pancreatic cancer cells, PANC-1 cells were incubated in a medium alone or a
medium containing mithramycin (0.1 µmol/L) with or without lactacystin (2
µmol/L) or TA (20 µmol/L) with or without lactacystin (2 µmol/L) for 24 hours.
Lactacystin is a selective inhibitor of the proteasome. Cells that were treated with
0.1% DMSO was set as control to TA treatment. Western blot results showed
that Sp1 protein level was down-regulated by both mithramycin and TA treatment
without lactacystin. However, when cells were treated with both TA and
lactacystin, Sp1 protein level was not decreased. Thus, TA appears to activate
proteasome-dependent Sp1 degradation, while mithramycin does not affect
proteasome-dependent

Sp1

degradation

because

the

combination

of

mithramycin and lactacystin down-regulated Sp1 protein to the same level as
mithramycin alone. This result shows that both mithramycin and TA downregulate Sp1 protein expression but through different mechanism.
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Figure 26 Through different mechanism tolfenamic acid mithramycin treatments
down-regulate Sp1 in vitro PANC-1 cells were incubated in medium alone or a
medium containing DMSO (0.1%), mithramycin (0.1 µmol/L), TA (20 µmol/L) or
lactacystin (2 µmol/L) as shown. Total protein lysates were harvested from the cell
cultures, and the level of Sp1 protein expression was determined using Western blot
analysis. Equal protein-sample loading was monitored by probing the same membrane
filter with an anti- GAPDH antibody.
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Synergistic cytotoxicity of mithramycin and tolfenamic acid in human
pancreatic cell lines in vitro

MTT assay was performed to determine the pancreatic cancer cell killing effect in
vitro. FG and BxPC3 cells were treated with mithramycin (0.025, 0.05, 0.1, 0.2,
0.4 µmol/L) and/or TA (2.5, 5, 10, 20, 40 µmol/L) for 24 to 48 hours. Figure 27
shows the MTT results. Drug concentration was optimized to the extent in which
there is no extensive cytotoxic effect by a single drug treatment. Under the
condition, mithramycin and TA showed higher cell killing effect in combination
treatment.

To determine the type of mithramycin and TA treatment interaction effect, the
MTT cell experimental data were subjected to further statistical analysis. Loewe
additivity model, one of the general reference models for evaluating drug
interactions, was used [232]. Based on this model, S-PLUS/R was used to
evaluate mithramycin and TA interaction. Basically Chou and Talalay’s median
effect equation was used to do the calculation [233]. FG (Fig 28) and BxPC3 (Fig
29) analyses output were shown. Table 1 shows the estimated interaction indices
from the corresponding fitted dose-effect curve (Fig. 28 A2 and B2) respectively.
Table 2 shows the estimated interaction indices from the corresponding fitted
dose-effect curve (Fig. 29 A2 and B2) respectively. The interaction was
considered to be synergy if the interaction index is < 1, while was considered to
be additivity when interaction index is equal to 1 [232]. When the standard
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deviation is span 1, the interaction was also considered to be additivity for
restriction analysis. All of the calculated interaction indexes were less than 1. But
in Fig. 28, 4 of the 5 of 24 hours and all 48 hours data points and in Fig. 29, 3 of
the 5 of 24 hours and all 48 hours data points that were considered to be synergy
for restriction analysis. This experimental result indicated that the combination of
mithramycin and TA produced synergistic cytotoxicity on FG and BxPC3 cells in
vitro.
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Figure 27 Mithramycin and tolfenamic acid treatment inhibit cell growth in vitro FG
(A) and BxPC3 (B) cells were treated with mithramycin at concentrations ranging from
0.025 to 0.4 µmol/L and TA from 2.5 to 40 µmol/L for 24 (A1, B1) and 48 hrs (A2, B2).
Cytotoxicity

was

assessed

using

the

3-(4,

5-dimethylthiazol-2-yl)-2,

5-

diphenyltetrazolium bromide assay.
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Figure 28 Synergistic cytotoxicity of mithramycin and tolfenamic acid in vitro in
FG cell MTT assay data of FG cell in Figure 26 was analyzed with S-PLUS/R software
using Chou and Talalay’s median effect equation. A, 24 hours data. B, 48 hours data.
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Figure 29 Synergistic cytotoxicity of mithramycin and tolfenamic acid in vitro in
BxPC3 cell MTT assay data of BxPC3 cell in Figure 26 was analyzed with S-PLUS/R
software using Chou and Talalay’s median effect equation. A, 24 hours data. B, 48 hours
data.
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Table 1 Statistics of interaction of mithramycin and tolfenamic acid in the FG cell cytotoxicity
experiment

Time Point

Interaction Additivity
Mithramycin

TA

(nmol/L)

(µmol/L)

Estimated
Value

95% confidential

Conclusion

interval

25

2.5

0.156

[0.047, 0.515]

Synergy

50

5

0.156

[0.046, 0.531]

Synergy

24 hours 100

20

0.133

[0.042, 0.558]

Synergy

200

20

0.188

[0.048, 0.740]

Synergy

400

40

0.289

[0.069, 1.205]

Additivity

25

2.5

0.0018

[0.0008, 0.0043]

Synergy

50

5

0.0030

[0.0013, 0.0071]

Synergy

48 hours 100

20

0.0050

[0.0020, 0.0122]

Synergy

200

20

0.0042

[0.0014, 0.0128]

Synergy

400

40

0.0059

[0.0018, 0.0198]

Synergy
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Table 2 Statistics of interaction of mithramycin and tolfenamic acid in the BxPC3 cell
cytotoxicity experiment

Time Point

Interaction Additivity
Mithramycin

TA

(nmol/L)

(µmol/L)

Estimated
Value

95% confidential

Conclusion

interval

25

2.5

0.177

[0.093, 1.090]

Additivity

50

5

0.127

[0.086, 1.043]

Additivity

24 hours 100

20

0.081

[0.018, 0.377]

Synergy

200

20

0.300

[0.026, 0.615]

Synergy

400

40

0.317

[0.034, 0.921]

Synergy

25

2.5

0.0046

[0.0014, 0.0150]

Synergy

50

5

0.0029

[0.0008, 0.0111]

Synergy

48 hours 100

20

0.0029

[0.0007, 0.0118]

Synergy

200

20

0.0059

[0.0014, 0.0243]

Synergy

400

40

0.0066

[0.0015, 0.0291]

Synergy
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Effects of treatment with mithramycin and tolfenamic acid on Sp1
recruitment into the Sp1 and VEGF promoter in vitro

In the present experiments, I sought to determine whether treatment with
tolfenamic acid and mithramycin regulated Sp1 expression at the transcriptional
level. Luciferase assay was performed. Briefly, Sp1 and VEGF (Fig.30A)
promoter reporter constructs were transfected into PANC-1 cells and then
incubated the cells in 0.01 µmol/L mithramycin or 5 µmol/L tolfenamic acid in
culture medium. In vitro, treatment with tolfenamic at did not suppress Sp1 and
VEGF promoter activity much, whereas treatment with mithramycin has certain
inhibition effect. However, the suppressing ability of mithramycin to Sp1 and
VEGF promoter were eliminated by further deletion of Sp1-binding sites in the
promoters. Furthermore, combination treatment of mithramycin and TA suppress
VEGF (Fig. 30B) and Sp1 (Fig. 30C) promoter activity significantly.

Next ChIP assay was performed as described in Material and Methods. The
experimental results were consistent with Luciferase assay results. Mithramycin
treatment reduced Sp1recruitment to its own and VEGF promoter as shown in
Figure 31. While treatment with TA has minor affect on Sp1 recruitment to its
own and VEGF promoter in vitro (Fig. 31). In contrast, treatment with
mithramycin and TA combination suppressed Sp1 protein recruitment to its own
promoter and VEGF promoter significantly. These data suggested that

110

mithramycin and TA combination treatment synergistic reduced Sp1 recruitment
to its own and VEGF promoter.
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Figure 30 Effects of tolfenamic acid and mithramycin treatment on Sp1 and VEGF
promoter activity in vitro. A, schematic structures of the minimal VEGF promoters. The
nucleotide positions and sequences of Sp1-binding sites and PCR forward and reverse
primers flanking those sites for ChIP assay are shown. B, VEGF and C, Sp1 promoter
reporter constructs were transfected into PANC-1 cells in triplicate and incubated for 12
h. The cells were then incubated for another 24 h in medium alone or a medium
containing 0.01µmol/L mithramycin or 5 µmol/L TA. Total protein lysates were harvested
from the cell cultures for measurement of promoter activity using a luciferase assay kit.
The relative promoter activities were assessed, and the activity in treated groups was
expressed as the fold change of that in their respective control groups. * P < 0.05 in a
comparison between the treated and respective control groups.
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Figure 31 Effects of mithramycin and tolfenamic acid on Sp1 and VEGF promoter
in vitro Chromatin Immunoprecipitation was performed as described in Materials and
Methods. Chromatin was extracted from PANC-1 cells that were incubated in vitro for 2
d in medium alone or a medium containing 0.5 µmol/l mithramycin, 50 µmol/l TA, 0.5
µmol/L mithramycin + 50 µmol/L TA (M+T). A specific anti-Sp1 antibody and
oligonucleotides flanking the (A) Sp1, (B) VEGF promoter regions containing Sp1binding sites was used. Lane 1, input chromatin DNA; lane 2, chromatin DNA with
control IgG; lane 3, chromatin DNA with anti-Sp1 antibody.
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Anti-angiogenesis effects of mithramycin and tolfenamic acid in vitro
Pancreatic cancer cell PANC-1 was treated with 50 µmol/L tolfenamic acid and/or
0.1 µmol/L mithramycin. Western blot was used to determine Sp1 protein
alternation in these cells. Sp1 expression down-regulation was confirmed.
Endothelial cell tube formation assay was used to determine the angiogenic
potential of the supernatants of PANC-1 culture. The degree of tube formation
was assessed as the percentage of cell surface area versus the total surface
area (Fig. 32A). Representative photomicrographs were taken in situ for tube
formation of HUVECs incubated in the supernatants (Fig. 32B). Mithramycin
and/or tolfenamic acid treatment reduced the capacity of supernatants of PANC1 cells to stimulate tube formation of endothelial cells compared with the capacity
of supernatants of control PANC-1 cells. The impaired angiogenic potential was
confirmed further by in vivo Matrigel plug assay (Fig. 32C) (protocol was
described in Material and Methods). These data indicated that mithramycin
and/or tolfenamic acid treatment reduced the angiogenic potential of PANC-1
cells.
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Figure 32

Mithramycin and tolfenamic acid treatment affect PANC-1 cell

angiogenic phenotype A, Culture supernatants were harvested from PANC-1 cells
treated with 0.5 µmol/L mithramycin, 50 µmol/L TA, 0.5µmol/L mithramycin + 50µmol/L
TA respectively. The angiogenic potentials of the supernatants were determined by an
endothelial cell tube formation assay. Representative pictures were taken in situ for tube
formation in the supernatant of the above 4 groups. (B) The degree of tube formation
was assessed as the percentage of cell surface area versus total surface area. Control
cell cultures were given arbitrary percentage values of 100. C, For a Matrigel plug assay,
Matrigel (200 µl) that contained 2×106 PANC-1 cells or PANC-1 cells treated with 0.5
µmol/L mithramycin, 50 µmol/LTA or 0.5 µmol/L mithramycin + 50µmol/L TA was used
as described in the text (see Materials and Methods). It is noteworthy that the downregulation of Sp1 expression impaired the angiogenic potential of pancreatic cancer cells
in vitro and in vivo. * P < 0.05 in a comparison between the treated and respective
control groups.
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Antitumor effects of mithramycin and tolfenamic acid in human pancreatic
cancer xenograft mouse models
Both mithramycin and TA treatment can down-regulate Sp1, VEGF and VEGFR
[225, 226]. However, it is unknown whether these two drugs interact
synergistically in regulating Sp1 activity and tumor growth. To determine the two
drugs’ function on tumor in vivo, PANC-1 xenograft tumor mouse model was
used. Specifically, dose-response experiments were performed. The animals with
PANC-1 xenograft tumor were given different doses of mithramycin (0.1, 0.4, and
1.5 mg/kg; Fig. 33A) via intraperitoneal injection twice a week and TA (10, 40, 80
mg/kg) via oral gavage three times a week. It was found that treatment with
mithramycin and TA produced dose-dependent antitumor activity. But the mouse
body weight, as a drug cytotoxicity index, also decreased in a dose-dependent
manner (Fig. 33B).
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Figure 33 Anti-tumor activity of mithramycin and tolfenamic acid treatment in vivo
A-B, Dose-dependent antitumor effects of mithramycin and TA in xenograft models of
human pancreatic cancer. A, PANC-1 cells were injected into the subcutis of nude mice
(n = 5). When tumors reached around 4 mm in diameter, the animals received different
doses of (A1) mithramycin (0.1, 0.4, 1.5mg/kg) via i.p. injection twice a week, (A2) TA
(10, 40, 80 mg/kg) via oral gavage three times a week. Tumors were weighted at the
time of experiment termination. (B) Mice bodies were also weighted at the same time.
Columns, mean weights; bars, SD. * P < 0.05 in a comparison between the treated and
respective control groups.
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Next, an experiment using PANC-1 tumor cell mouse models in which PBS,
mithramycin (0. 1mg/kg), TA (10mg/kg), or M+T were administered to a group of
nude mice was performed. It was found that administration of TA or mithramycin
alone produced minor antitumor activity. In contrast, administration of
mithramycin and TA produced significant antitumor activity (Fig. 34A1 and 34A2).
Furthermore, the use of low dose of TA and MIT produced synergistic antitumor
activity without producing significant systemic side toxicity, as indicated by a lack
of significant weight loss (Fig. 34B). Therefore, the use of low dose of TA and
mithramycin produced significant antitumor activity without toxicity. This suggests
that treatment with low dose of mithramycin and TA has a significant therapeutic
benefit.
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Figure 34 Synergistic anti-tumor activity of mithramycin and tolfenamic acid in
vivo Parallel to Figure 33, a group of mice with PANC-1 tumor were treated with
0.1mg/kg mithramycin and 10mg/kg TA. A1, All the 4 groups of mice tumors were
measured once every week, and at each measurement, the mean ± SD tumor volume in
the five mice in each group was calculated. Tumor weight (A2) and mice body weights
(B) were measured at the end of the experiment. A3 and A4, Representative mouse and
the tumor from each group. * P < 0.05 in a comparison between the treated and
respective control groups.
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Effects of mithramycin and tolfenamic acid treatment on gene expression
and Sp1 recruitment on Sp1 and VEGF promoters in Vivo
To determine the gene expression alternation with treatment of mithramycin and
TA, immunohistochemistry staining was performed using the PANC-1 tumor
tissue collected from mice that received treatment with PBS, TA, mithramycin, or
T+M. As shown in Fig. 35, treatment with TA or mithramycin alone can decrease
expression of Sp1 and its downstream molecule VEGF. Tumor microvessel
density, shown with CD31 staining, also decreased comparing with control group.
Whereas mithramycin and TA combination treatment suppressed Sp1 and VEGF
expression dramatically, this was consistent with the much reduced MVD.
Besides these, mithramycin and/or TA treatment decreased tumor PCNA protein
level, especially in combination treatment. These data suggested that the
synergy anti-tumor activity of mithramycin and TA combination may be produced
through not only anti-angiogenesis effect, but also the direct growth inhibition of
tumor cell proliferation. Indeed, there is also the synergy low-dose combination
cytotoxicity, but no cytotoxicity when use alone, in vivo.
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Figure 35 Analysis of gene expression and microvessel formation in tumor tissues
The tumor tissues described in Fig. 33 were collected and processed to do
immunohistochemistry staining of Sp1, VEGF, PCNA and micro-blood-vessel as
described in Materials and Methods.
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To confirm the Sp1 and VEGF alternation, western blot analysis was then
performed. Total protein lysates extracted from the PANC-1 tumor tissue
specimens collected from mice that received treatment with PBS, TA,
mithramycin, or T+M were used. As shown in Fig. 36A, Sp1 and VEGF protein
were down-regulated especially in the combination treatment. BxPC3 tumor
tissue collected from mice that received the same treatment was also analyzed
(Fig. 36 B).

Then I sought to determine whether Sp1 transcription was regulated by TA and
mithramycin treatment in vivo. Similar to in vitro, mithramycin treatment reduced
Sp1recruitment onto its own and VEGF promoter as shown in the ChIP assay.
While treatment with TA has minor affect on Sp1 recruitment to its own and
VEGF promoter in vitro (Fig. 37). In contrast, treatment with mithramycin and TA
suppressed Sp1 protein recruitment to its own promoter significantly.

These data suggested that mithramycin and TA combination treatment
synergistic down-regulates Sp1 and VEGF expression and produces tumor
suppression effect in vivo.
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Figure 36 Effects of treatment with mithramycin and tolfenamic acid on Sp1
protein level The tumor tissues described in Fig. 34 were collected and processed as
described in Materials and Methods. A-B, total protein lysates were harvested from
tumor tissues and the level of protein expression in them was determined using Western
blot analysis. Equal protein-sample loading was monitored by probing the same
membrane filter with an anti–GAPDH antibody. A, PANC-1 xenograft tumors; B, BxPC3
tumors.
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Figure 37 Effects of mithramycin and tolfenamic acid treatment on Sp1 and VEGF
promoter in vivo Chromatin Immunoprecipitation was performed as described in
Materials and Methods. Chromatin extracted from tumor tissues described in Fig. 34
were collected and processed. A specific anti-Sp1 antibody and oligonucleotides flanking
the (A) Sp1, (B) VEGF promoter regions containing Sp1-binding sites was used. Lane 1,
input chromatin DNA; lane 2, chromatin DNA with control IgG; lane 3, chromatin DNA
with anti-Sp1 antibody.
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DISCUSSION
In this chapter, it was found that metronomic low dose of mithramycin and
tolfenamic acid combination synergistic down-regulates Sp1 expression, which is
a key positive regulator of various angiogenic factors expression including VEGF
and produced synergistic anti-tumor therapeutic effect on xenograft tumor grown
in nude mice. This therapeutic effect was consistent with Sp1 activity
suppression and the down-regulation of its downstream angiogenic molecules.
The experimental results indicate that mithramycin targets Sp1 at its transcription
level through competition its recruitment on the Sp1 sites. But tolfenamic acid
promotes Sp1 protein degradation. These findings showed researchers the
synergistic down regulation of transcription factor Sp1 and would further drive a
new rational of drug combination to target a protein molecule at different
biological level.

Angiogenesis plays important roles in tumor growth and metastasis. Studies
have been shown that both Sp1 and VEGF are important to pancreatic cancer
angiogenesis [130, 225]. Currently targeting of VEGF signaling and function is
still a hot spot in anti- angiogenesis, growth, and metastasis of most tumor type.
Strategies have been developed, including the use of anti-VEGF antibodies,
targeting VEGF receptors to directly interfere the signal effect [124, 125].
Additionally, multiple genes, identified in pancreatic cancer switch of the
"angiogenic network" [126, 127], were also proposed to be the anti-angiogenic
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targets and targeted in experimental mouse model [58, 128]. These reported
clinical research results and experimental studies using different approaches
showed the crucial role of the angiogenic process in pancreatic cancer. Also,
replication deficient recombinant adenovirus mediated was evaluated in human
pancreatic cancer mouse model and shown to be efficient gene therapy for
pancreatic carcinoma [129].

In methodology, visualized fluorescence imaging was developed in tumor
angiogenesis research in nude mice based on the stably green fluorescent
protein expression cancer cell lines and mouse models [234, 235]. Recently,
multicolored fluorescent proteins were used to develop color-coded fluorescent
protein imaging models of tumor angiogenesis [236]. The generally termed
AngioMouse

can

quantitatively

determine

efficacy

of

anti-angiogenesis

compounds through visualizing the details of the tumor-induced angiogenesis.

As a regulator of the important pro-angiogenic molecules, Sp1 can be regulated
by mithramycin through direct competition of Sp1 recruitment on Sp1 sites in Sp1
promoter as it was shown in last chapter. During the regulation, Sp1 protein level
change would appear until the mRNA synthesized before mithramycin binds Sp1
sites, which will take certain time. This is consistent with the observation of
continuous high dose of mithramycin was needed to obtain significant tumor
inhibition which leads to the significant cytotoxicity. Although mithramycin can
effectively block Sp1 mRNA synthesis, the abundance and strong stability of Sp1
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protein prevents mithramycin from rapid down-regulation of Sp1 protein in the
tumor cells. In this chapter, it was demonstrated that tolfenamic acid can promote
Sp1 protein degradation. More importantly, combined use of mithramycin and
tolfenamic acid, neither of which has significant effects on Sp1 protein
expression, led to substantial down-regulation of Sp1 protein, which was
consistent with a synergistic antitumor effect in mouse models.

Studies have shown that a number of non-steroidal anti-inflammation drugs have
anti-angiogenesis activity in a wide variety of xenograft models. Celecoxib and
tolfenamic acid were shown to decrease pancreatic tumor growth and metastasis
in nude mice [130, 225]. The drugs activate Sp1, Sp3, and Sp4 protein
degradation and inhibit VEGF mRNA synthesis and protein expression in
pancreatic cancer cells. Sp1 was reported to be over-expressed in human
pancreatic cancer and associated with poor survival [61, 109, 237]. Evidences
have been provided that transcription factor Sp1 regulates VEGF expression in
pancreatic cancer cells. In Sp protein family, Sp1, Sp3 and Sp4 are more closely
related and form a monophyletic group [238]. Experimental results showed that
through the activation of proteasome-dependent degradation of Sp protein,
tolfenamic acid exhibited growth inhibitory effect by anti-angiogenic strategy.
However, down-regulation of Sp1 by mithramycin treatment is mostly involved in
transcription repression of Sp1 mRNA. Therefore, mithramycin and tolfenamic
acid have distinct mechanisms of actions in regulation of Sp1 expression and

127

activities, and their interaction forms the molecular basis for their synergistic antiangiogenesis and antitumor activities.

In addition to its anti-angiogenic function reported, down-regulation of Sp1 also
may cause the altered expression of genes important to cell survival, a
mechanism that is likely for the antitumor activities of tolfenamic acid and
mithramycin. For example, tolfenamic acid treatment activates Sp protein
degradation, decreases Sp proteins binding to survivin promoter and inhibits
survivin expression in pancreatic cancer cell and subsequently sensitizes the
pancreatic cancer cell to radiotherapy [239]. Consistently, the data in this chapter
also shows tolfenamic acid inhibits tumor cell growth in vitro and the effect was
synergized when combined with mithramycin (Table1, 2 and Figure 28, 29).
Altered expression of survivin expression may be one of the mechanisms
underlying the cytotoxic effect of tolfenamic acid and mithramycin.

Although the data showed tolfenamic acid treatment has minor effect on the
recruitment of Sp1 on its own and VEGF promoter (Figure 31). Tolfenamic acid
did affect the Sp1 promoter activity and VEGF promoter activity (Figure 30). The
possible anti-angiogenic effect of tolfenamic acid may be rely on decreasing total
Sp1 protein quality but not the interference of the physical contact of Sp1 and its
binding sites in the promoters which needs to be further investigated.
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Figure 38 Schematic model of
mithramycin and tolfenamic acid
on Sp1
A, mithramycin treatment physically
blocks Sp1 binding to Sp1 sites in
its own and its downstream
molecules but may leads to a
negative feedback to Sp1 protein
degradation
B, tolfenamic acid treatment facilitate
Sp1 protein degradation and may
cause its trans-activation mRNA
transcription
C, mithramycin and TA combination
treatment blocks trans-activation
and facilitate its degradation which
blocks the negative feedbacks and
produce synergistic effect
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Due to the insoluble character in water, tolfenamic acid was shown to need about
100 times in concentration to have the similar cell growth inhibition affect in vitro
(Figure 27). The limit leads to the relatively low therapeutic index. Polymer-drug
conjugates nanoparticles, one of the major categories of targeted drug delivery
system, are synthetic water-soluble polymers used as the drug carriers [240].
Compare with the corresponding parent drugs, the clinical trial results of polymerdrug conjugates nanoparticles have several advantages including decreased
side effects, enhanced therapeutic efficacy, ease drug administration, and
improved patient compliance. Tolfenamic acid may be more effective by linking
with nanocarriers, which brings more drugs to the tumor site and reduces
exposure of normal tissues to the drug.

As our experimental results showed mithramycin has significant cytotoxicity when
it produces significant antitumor effect as a single drug using mouse body weight
change as the measurement. When tolfenamic acid was used together, Sp1
protein was synergistic down-regulated through different level and tumor growth
was significant inhibited. But no detectable cytotoxicity was observed.
Mithramycin nanoparticle has been developed [241]. Polylactide co-glycoide
(PLGA) based mithramycin nanoparticle inhibited RAW264 macrophages and
smooth muscle cells and reduced the number of circulating monocytes in rabbits.
A nanoparticle with homing moiety actively binding to target cell has been widely
demonstrated. It was shown that the interaction makes more drug compounds
gathering at the diseased sites, whereas systemic drug exposure was reduced
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and subsequently minimized cytotoxicity. One category of the homing moieties is
antibody including intact antibody, fragments (Fab’ or (Fab)2) or genetically
engineered Fv. In addition to some certain carbohydrates, transferrin was
proposed as a homing moiety. Compare with antibody, its potential advantages is
the risk of immune response is rather low because of the present of transferrin in
organism in high concentrations [242, 243]. The pharmacodynamics and
pharmacokinetics properties of mithramycin encapsulated by nanoparticle with
home moiety should be an interesting topic to be investigated.

As our experimental results showed mithramycin has significant cytotoxicity when
it produces significant antitumor effect as a single drug using mouse body weight
change as the measurement. When mithramycin and tolfenamic acid were used
together, Sp1 protein was synergistic down-regulated through different level and
tumor growth was significant inhibited. But no detectable cytotoxicity was
observed. Our data suggested that the combination of mithramycin and
tolfenamic acid could achieve highest therapeutic index.

Collectively, our study suggests that mithramycin competing Sp1 recruitment to
Sp1 sites on both Sp1 and VEGF promoters. Tolfenamic acid does not have the
competing ability but it down-regulates Sp1 protein level by direct targeting Sp1
at protein level. The metronomic low dose use of mithramycin in combination with
tolfenamic acid is a novel strategy of targeting angiogenic molecule Sp1 at both
transcriptional and protein degradation level. Combining mithramycin and
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tolfenamic acid in cancer clinical studies could represent a rationale step forward.
This

double

targeting

from

different

level

strategy

would

develop

effective targeted therapy for pancreatic cancer and other cancers.
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CONCLUSION
Chapter I of this dissertation demonstrated that knockdown Sp1 protein downregulates Sp1 downstream angiogenic factors, significantly reduced pancreatic
cancer cell angiogenic potential in vitro and led to the angiogenic phenotypic
change in vivo. All of the experimental results suggest that Sp1 is a key factor for
pancreatic cancer angiogenesis.

Chapter II shows that Bevacizumab treatment up-regulates Sp1 and VEGF
protein in xenograft tumor tissue, which may trigger drug resistance to
Bevacizumab in turn. This positive feedback mechanism trans-activate Sp1 and
its downstream angiogenic factors’ over-expression subsequently. Combination
of mithramycin with Bevacizumab produced synergistic antitumor activity by both
interposing upstream Sp1 transcriptional regulation and neutralizing downstream
effecter molecules such as VEGF.

Chapter III shows the experimental evidence that mithramycin competes Sp1
recruitment to Sp1 sites on both Sp1 and VEGF promoters. Tolfenamic acid does
not have the competing ability but it down-regulates Sp1 protein level by direct
targeting Sp1 protein. The metronomic low dose use of mithramycin
in combination with tolfenamic acid is an important novel strategy of targeting
angiogenic molecule Sp1 at both transcriptional and protein degradation level.
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Collectively, in this dissertation new metronomic anti-angiogenic therapy
strategies of pancreatic cancer were designed and tested on mouse models. The
novel findings may provide both theoretical and practical direction to clinic
practice. The proposed rationales may push the development of effective target
therapy step forward for pancreatic cancer and other cancers. Hopefully, the
experimental therapeutic designs may be translated to clinic and benefit
pancreatic cancer patients in the near future.
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